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ABSTRACT 
TB (tuberculosis), caused by Mycobacterium tuberculosis (Mtb), continues to be a world-
leading killer and a serious global health problem primarily affecting poor people in many 
developing countries. The difficult situation with TB/HIV co-infection is also a major key 
challenge to public health. Despite recent advances in TB research, the host- and pathogen-
specific factors that lead to protective immunity, particularly in humans, remain unclear. While 
it is well-established that cell-mediated immunity is required to control TB infection, the role of 
humoral immunity including Th2 immune responses is debated. This thesis aimed to explore 
immune responses in human TB and the immunopathogenic mechanisms involved in the 
progression of clinical TB in both HIV-negative and HIV-positive individuals. 
To address the aims of this thesis work, well-defined study cohorts of active TB patients were 
obtained in close collaboration with the Black Lion University Hospital in Addis Ababa, 
Ethiopia. We used a novel immunodiagnostic test, Antibodies in Lymphocyte Supernatants 
(ALS), to demonstrate that IgG-secreting plasmablasts were significantly higher in the 
peripheral circulation of patients with active TB compared to latent TB cases and non-TB 
controls. Interestingly, BCG-specific IgG titers were particularly high in blood samples from 
TB/HIV co-infected patients with CD4 T cell counts <200 cells/ml who produced low levels 
of Mtb-specific IFN-γ in vitro. A technological platform including quantitative assessments 
of mRNA and protein expression in tissue (lymph nodes), fluids (bronchoalveolar lavage 
(BAL) and pleura fluid) and peripheral blood, was also used to investigate antimicrobial 
effector pathways and adverse immune responses in unique clinical samples obtained from the 
local site of Mtb infection. The results from these studies revealed that TB disease was 
associated with extensive tissue remodelling including an altered cellular composition, 
collagen deposition and granuloma formation. Here, the degree of necrotic granuloma 
formation was particularly prominent in TB/HIV-co-infected patients. Despite granuloma 
enrichment of activated CD68+ macrophages containing Mtb-antigens, mRNA levels of IFN-
γ, TNF-α and IL-17 remained low in Mtb-infected lymph nodes. Accordingly, CD8+ T cells 
expressing cytolytic and antimicrobial effector molecules perforin and granulysin were low 
inside the TB lesions, while CD4+FoxP3+ regulatory T cells (Treg) and Th2/Treg cell 
cytokines IL-13 and TGF-β were up-regulated in the Mtb-infected tissues. The observed shift 
of the immune response from a Th1/Th17 towards an immunoregulatory phenotype was 
supported by our finding of a Th2 polarized response in the lung of patients with pulmonary 
TB. Here, multiplex protein analysis of BAL and plasma samples demonstrated low levels of 
Th1/Th17 cytokines and the T cell-chemoattractant CCL5, but significantly up-regulated 
levels of pro-inflammatory cytokines and the Th2 cytokine IL-4. The enhanced Th2 response 
was associated with increased levels of CCL4, suppressors of cytokine signaling-3 (SOCS3) 
and mycobacteria-specific IgG in BAL fluid from patients with active pulmonary TB. 
Contrary, IL-4, CCL4, SOCS3 and IgG-responses remained low in patients with less severe 
extrapulmonary pleural TB disease, who demonstrated up-regulated levels of both IFN-γ and 
CCL5. 
Taken together, our results provide evidence that human TB is associated with impaired Th1 
immunity but elevated Th2/immunoregulatory responses and induction of antibody-mediated 
immunity. Importantly, enhanced Th2 and/or plasmablast responses may be used as relevant 
biomarkers or immune response signatures of active progressive TB disease that could be 
explored as potential targets for clinical TB management in the future. 
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1 INTRODUCTION TO THE THESIS 
Tuberculosis (TB) is a serious global health problem and after HIV, TB is ranked as the 
second leading cause of death from infectious disease worldwide. The global burden of 
TB is enormous with about 9 million new cases in 2011, accounting for 1.4 million 
deaths of which 430000 were HIV-associated TB deaths [1]. In parallel with the 
problems related to TB/HIV co-infection, the emergence of multidrug resistant (MDR) 
and extensively drug resistant (XDR) TB has increased the need to address the clinical 
problems with TB more effectively. About 80% of all TB cases are found in developing 
or low-income countries primarily in Africa, Asia and Eastern-Europe, where the 
resources to successfully diagnose and treat TB is limited. Importantly, diagnosis of 
active TB is complicated, particularly among immunosuppressed TB/HIV co-infected 
patients. A delay in TB diagnosis and proper treatment will lead to a continuous spread 
of TB.  
Mycobacterium tuberculosis (Mtb) was discovered by Robert Koch in 1882 as the 
bacteria that causes TB. A heat-killed extract generated from the tubercle bacilli was 
later developed as the first diagnostic method, the Tuberculin Skin Test (TST), by 
Charles Mantoux in 1907 [2]. Even though the specificity of the TST to detect active 
TB disease is low, this method is still extensively used in clinical routine practice due 
to the lack of better diagnostic tests. The only existing TB vaccine is the Bacillus 
Calmette Guerin (BCG), which was introduced in 1921. Unfortunately, the protective 
efficacy of BCG is highly variable (0-80%) [3] and thus new and better vaccine 
regimens are required. Despite a lot of recent advances in TB immunology research, the 
host response required for protective in human TB has not been clearly defined. 
Therefore the search for specific biomarkers or immune signatures of active TB will 
continue in order to develop better diagnostic tests as well as novel concepts for 
vaccines and drugs that could prevent transmission of TB. 
In the Background section of this thesis, I will present the Mtb bacteria, the host 
immune response in TB, and the clinical characteristics of TB as well as available 
diagnostic methods to detect active TB disease. Thereafter, I will present the specific 
aims, study design and methods used in this thesis work, followed by a presentation and 
discussion of the results of the thesis.  
 2 
2 BACKGROUND 
 
2.1 TB INFECTION: A LONG JOURNEY 
2.1.1 History of TB 
TB has existed together with humans for a long time. Skeletons carrying lesions 
apparently caused by spinal TB have been identified from Stone Age skeletons and 
Egyptian mummies that are around 5,000 years old [4]. Archaeological evidence of TB 
scars on the lungs of a mummified body comes from early Han dynasty (206BC-7AD). 
These diseases were given different names and were thought of as separate diseases. 
The term pulmonary consumption was used to label pulmonary TB, scrofula described 
TB of the lymph nodes and Lupus vulgaris was the term used to describe TB of the skin 
[5]. The idea of a single cause for the different forms of TB was advanced by Laennec 
at the start of the 19th century. Although it was not until the experimental work 
performed by Villermin in 1865 and by Koch in 1882 that the present concept of TB as 
a single disease caused by the tubercle bacillus emerged.  
 
2.1.2 Epidemiology of TB 
TB results in an estimated 1.7 million deaths each year and the worldwide number of 
new cases is all-time high [6]. The World Health Organization (WHO) reported 8.8 
million new TB cases in 2010, with about 25% occurring among people living with 
HIV [7]. In addition, 1/3 of the world population is estimated to be carriers of latent 
TB infection [8]. Although the reliability of epidemiological assessments has 
progressively improved, only around 30% of the people suffering from TB receive a 
confirmed diagnosis of active TB [1]. 
TB is a disease of poverty that thrives where social and economic determinants of ill 
health prevail and it affects mostly young adults in their most productive years [1]. 
Thus, more than 80% of all TB cases in the world are found in 22 low- and middle-
income countries; thirteen in Africa and nine in Asia. Due to the devastating effect of 
HIV on the susceptibility to TB, sub-Saharan Africa has been disproportionately 
affected and accounts for around 80% of all TB/HIV co-infected cases [6]. In endemic 
areas, an estimated 15-20% of TB cases are seen in children [7]. According to the 
WHO, rates of MDR-TB are the highest in Eastern Europe, where around 20 % of all 
new TB cases are MDR-TB. In some parts of the former Soviet Union, up to 25-30% of 
new TB cases are MDR-TB. 
Ethiopia is ranked as number 7 out of the 22 high-burden countries in the world, with a 
TB prevalence of 237 per 100,000 populations. In 2011, only 47% of all new 
pulmonary TB (PTB) cases were sputum-smear positive for Mtb, while most 
extrapulmonary (EPTB) forms of TB were diagnosed using invasive techniques or 
clinical diagnosis only, which stress the need for new diagnostic methods. The HIV 
prevalence in incident TB cases is 17%, while 1,6% of all new TB cases have MDR-
TB [1]. Thus, in Ethiopia, TB/HIV co-infection is a larger public health problem than 
MDR-TB.   
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2.1.3 Transmission of TB in humans 
TB is an airborne disease [9] and Mtb is transmitted through aerosol droplets that 
remain suspended in the air for prolonged periods of time. Thus, Mtb usually enters 
the human host via the airways, which will result in one of the following outcomes 
(Figure 1): a) the host immune response clears the infection, but this is probably very 
rare, b) the host immune response controls the infection in a latent state, but is not 
sufficient to eradicate TB infection, c) the host immune response cannot control 
bacterial replication, which results in progression of active TB disease [10, 11].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. No infection, latent TB infection or active TB disease. Which factors will decide? 
 
The most common form of active disease is PTB, although the EPTB forms can be 
established in any organ in the body (Figure 2). The infectiousness of a person with 
progressive TB disease is a multifactorial event and depends on the clinical form of TB 
(only an open PTB is contagious), the bacterial load in the lungs, the area in which 
exposure occurs, the time of exposure and the susceptibility of the host [12]. A person 
with latent TB does not have any clinical symptoms and is not contagious, even though 
the bacteria persist in a dormant state in the infected organ [12].  Individuals with latent 
TB are estimated to have a lifetime risk of 5-10% to ever develop active TB disease. 
Clinical signs and symptoms of active TB will generally develop within 2 years after 
initial Mtb exposure [13]. Mtb can reside in human tissues for decades without active 
replication, but the bacteria maintain the ability to resume growth that could break 
latency and cause active TB. Thus, Mtb can exist in equilibrium with the host 
immune response for time periods that outcompete almost any other infectious 
disease [14]. Latent TB represents a significant obstacle to the control and eradication 
of TB because the non-replicating bacteria may be in a state of “drug indifference”, 
meaning the bugs cannot be effectively killed by anti-TB drugs [15]. 
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Figure 2. Clinical outcome of TB infection and disease. Mtb is an airborne pathogen that 
transmits via contagious aerosols. The primary site of infection is the lung, where a primary 
lesion is formed upon initial Mtb infection. 5-10% of Mtb infected individuals will develop 
active disease (pulmonary or extrapulmonary TB disease) while the remaining individuals will 
contain TB infection in a latent state. Reactivation of latent TB occurs if the immune system 
fails to control bacterial growth. If left untreated, primary TB will progress to more severe form 
of disease including systemic or miliary TB disease, which involves severe inflammation and 
tissue destruction in the lung that could also cause cavity formation. 
 
2.2 MTB: A COMPLEX BACTERIA 
2.2.1 The Genus Mycobacterium  
Mycobacteria are rod-shaped, facultative intracellular bacteria with a size of 2-4µm.  
There are over 100 mycobacterial species that are wide-spread in nature and the 
majority of these are non-pathogenic. The Mycobacterium tuberculosis complex 
consists of closely related species that cause disease in both humans and animals. The 
mycobacteria grouped in this complex differ widely in terms of their host tropisms and 
pathogenicity. Some are human pathogens (Mtb, M. africanum, M. canettii), whereas 
others such as M. bovis, have a wide spectrum of hosts [16]. While Mtb is the most 
pathogenic species in humans, the only existing vaccine against TB,  the BCG vaccine, 
was generated from a live attenuated strain of M. bovis, M. bovis BCG [17]. Mtb is also 
able to infect animals that have contact with humans, although experimental animals 
such as mice are not natural hosts of Mtb. Members of the genus Mycobacterium have 
a very complex cell wall envelope, which is responsible for the low permeability that is 
used as the characteristic differential feature in the staining procedure known as Ziehl-
Neelsen acid-fast stain [17]. Microscopic analysis of acid-fast stained clinical 
specimen, primarily sputum-smear samples, is the most common laboratory test used 
for TB diagnosis. Mtb is a slow-growing bacteria that replicates with a doubling time of 
12 to 24 hours [18], resulting in lengthy cultures of clinical specimens (4-8 weeks) that 
often cause delays in diagnosis.  
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2.2.2 Virulence of Mtb  
Once Mtb enters the respiratory tract, the bacteria are engulfed by alveolar 
macrophages [19]. Mtb has evolved strategies to survive inside macrophages even in 
the presence of inflammation. This involves a number of different virulence factors that 
have developed in the bacteria in response to the host immune response [17], and by 
which the bacteria can inhibit immune cell functions [20]. Inhibition of phagolysosomal 
fusion in Mtb-infected macrophages is a key mechanism used by Mtb to avoid 
intracellular destruction via the action of lysosomal hydrolases and an acidic 
environment [19]. It has also been shown that the amount of bacteria plays a role in 
the ability of the macrophage to control Mtb infection. Human macrophages were 
able to control infection with Mtb at a low multiplicity of infection (MOI) of 1, but 
not at a high MOI of 10 [21]. Accordingly, the acidification of mycobacterial 
phagosomes was also more efficient at MOI 1 compared to 10, which highlights the 
role of phagosomal acidification in the restriction of Mtb growth [21]. If the pressure 
from the immune system is too strong, Mtb bacilli stop their active replication and enter 
a dormant phase. Then the bacilli reside in the protective milieu of the phagosome in a 
state of non-replicating persistence [22]. Dormant bacilli maintain their ability to 
resume growth when conditions become favorable.  
The thick cell wall of Mtb contains mycolic acids that provide a special lipid barrier 
responsible for many of the physiological and disease-inducing aspects of Mtb [23]. 
Common anti-TB drugs such as isoniazid and ethionamide work by inhibiting synthesis 
of mycolic acid [24]. Another well-characterized virulence factor of Mtb is 
lipoarabinomannan (LAM), which is an abundant cell wall glycolipid [25]. Mtb has 
mannose-capped LAM (ManLAM), whereas LAM of less pathogenic mycobacteria 
lacks the Man-cap [26]. Thus, the type of LAM-capping is crucial for virulence [27]. 
There are multiple effects of Man-LAM on the host cell, but the interference of Man-
LAM with phagosomal maturation in macrophages is the best characterized [28]. 
Comparisons between M. bovis BCG and virulent Mtb have resulted in the 
identification of several genetic regions of difference [29-31]. Only one of these, region 
of difference 1 (RD1), is absent from every strain of BCG but present in every virulent 
Mtb strain tested [29]. Early secreted antigen target 6 (ESAT-6) is a protein encoded 
by RD1 and is a key component of the type VII secretion system, Esx-1, that has been 
shown to be a major virulence factor of Mtb [32-35]. Interestingly, virulent Mtb 
expressing Esx-1 can translocate from the phagosome and replicate inside the 
macrophage cytoplasm, causing significant cell death within a week [36]. As virulent 
Mtb reaches a threshold number of bacilli inside the human macrophage, ESAT-6-
dependent necrosis occurs [37]. Esx-1 may also be involved in the impairment of 
autophagy, a physiological process known to inhibit intracellular survival and spread of 
mycobacteria [38]. Thus, the proteins expressed by ESX-1, are responsible for the 
phagolysosomal escape seen in macrophages infected with virulent Mtb strains [36]. 
Furthermore,  peptides derived from RD1-encoded proteins including ESAT-6, CFP-10 
and TB10.4, have been explored in TB diagnosis [39, 40] as BCG vaccinated 
individuals or patients with mycobacterial infections other than TB do not respond to 
these Mtb-specific peptides [41]. 
Despite the discovery of a number of mechanisms used by Mtb to survive within the 
host to avoid immune defense mechanisms, the complex nature of TB infection and the 
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interaction of Mtb with the host, still remains poorly understood [42]. Due to the 
emergence of Mtb strains which are resistant to almost all available drugs, there is an 
urgent need to understand the molecular basis of this pathogen's success in causing 
disease in humans. 
 
2.3 TB IMMUNITY: INDUCTION OF CELLULAR IMMUNE RESPONSES  
Mtb is a persistent pathogen that is not easily cleared by the immune system and 
therefore a chronic disease develops. Control of TB infection depends on the 
development of efficient innate and adaptive immune responses at the site of 
infection. However, bacterial control requires an immunological balance and too little 
as well as too much inflammation can be harmful to the human host [43]. Many of the 
immune system´s cells and molecules that act during Mtb infection have multiple and 
redundant roles in a complex network of immune reactions. In active TB,  Mtb is able 
to manipulate certain arms of the immune response to provide a suitable environment 
for growth while promoting the immune-mediated damage required for transmission 
of disease [44].  
 
2.3.1 The innate immune response in TB 
The ability of the innate immune system to rapidly recognize and respond to invading 
microbes is essential for controlling infections. This is accomplished by the expression 
of pattern recognition receptors (PRRs) on macrophages and other leukocytes, which 
recognize and respond to microbial components [45, 46]. The PRRs recognize a diverse 
set of molecules generally classified as pathogen-associated molecular patterns 
(PAMPs) [47]. A particular set of PRRs, the mammalian Toll-like receptors (TLR), 
play an essential role in innate immunity by recognition of conserved PAMPs that 
initiate the activation of NF-κB and other intracellular signaling pathways through the 
adapter protein, MyD88 [45]. This allows the TLRs to detect the presence of infection 
and to induce activation of inflammatory and antimicrobial innate immune responses. 
Mtb primarily infects macrophages and modulate the cell´s bactericidal  mechanisms 
to create a suitable niche for bacterial survival and effective replication [48]. Innate 
resistance to Mtb is a key factor in disease outcome as only a small percentage of 
individuals exposed to this pathogen become actively infected [49]. The innate immune 
system responds to Mtb infection by producing pro-inflammatory cytokines leading to 
intercellular communication and cell recruitment to the site of infection. Mtb conserved 
PAMPs trigger the activation of diverse PRRs and innate mediators involved in the 
phagocytosis of mycobacteria and induction of signaling pathways that trigger 
production of inflammatory cytokines such as interleukin-12 (IL-12), tumor necrosis 
factor-α (TNF-α), and interleukin-1β (IL-1β) [50, 51].  Mtb enter host macrophages via 
binding to multiple PRR receptors types that could be used simultaneously [52]. These 
receptors belong to four main classes: opsonizing receptors (e.g. FcγR and complement 
receptors), scavenger receptors (e.g. CD36 and MARCO), C-type lectin receptors (e.g. 
mannose receptor, dectin-1 and 2, and DC-SIGN) and innate immune sensors (e.g. 
TLRs and NODs) [27, 53, 54].  
TLRs are essential for recognition of a broad repertoire of microbes by antigen-
presenting cells (APCs) such as macrophages and dendritic cells (DCs). Here, TLR2, 
TLR4 and TLR9 play an important role in the innate responses against Mtb [55-57]. 
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Accordingly, polymorphisms in TLR2 and TLR9 have been associated with increased 
susceptibility to TB in humans, confirming the importance of TLRs in the human host 
defense against mycobacteria [58]. The mycobacterial cell wall consists of a complex 
array of proteins and lipids, many of which have been shown to have immune 
modulatory activity [26]. These cell wall components have been shown to be released 
from infected macrophages as exosomes [59, 60] that stimulate a pro-inflammatory 
response in a TLR dependent manner [60]. Importantly, Mtb has also developed 
strategies to interfere with TLR activation and the induction of inflammation. 
Upon TB infection in the lung, initial activation of cells of the innate immune defense 
involves classically phagocytic cells such as resident alveolar macrophages, pulmonary 
DCs, monocytes and neutrophils [61]. Moreover, Mtb can also bind and interact with 
non-specialized phagocytic cells such as alveolar epithelial cells [62]. Inhaled 
mycobacteria are engulfed by alveolar macrophages that will become activated at the 
site of infection in the lung. Activated macrophages will produce reactive nitrogen 
intermediates (RNI) [63] as well as antimicrobial peptides that will comprise the first 
line of defense to limit intracellular bacterial replication [64]. Neutrophils are also 
acknowledged to confer protection by phagocytosis and killing of Mtb bacilli [65]. 
Death of the host macrophage is necessary for the bacilli to escape and infect new 
cells. It has been found that different modes of host cell death play different roles 
during microbial infections in terms of host defense and microbal survival [66, 67]. 
Apoptosis is a programmed cell death that is dependent on the induction of caspases, 
while necrosis is a passive form of cell death that is induced by different types of 
stress, inflammation or microbial infection [66, 68]. Here, Mtb has developed 
mechanisms to limit macrophage apoptosis [69, 70] and instead promote host cell 
necrosis, which can prevent cross-presentation of Mtb-antigens by DCs that could 
impede and delay T cell priming [71]. Accordingly, infection of macrophages with 
virulent Mtb above a certain MOI quickly reduces viability of the host cells, in a 
manner similar to necrosis rather than apoptosis [72, 73]. 
 
2.3.2 The adaptive immune response in TB 
Successful control of Mtb infection is dependent on the induction of cell-mediated 
immunity, which involves close interactions between innate and adaptive immune 
responses (Figure 3). Recognition of Mtb products by TLRs and other PRRs expressed 
on DCs triggers functional maturation of DCs and leads to initiation of antigen-specific 
adaptive immune responses [46]. Here, DCs that take up Mtb-infected cells or bacterial 
products in the lung are capable of migrating to the draining lymph nodes to initiate 
cross-presentation and activation of specific T cell responses [74]. After arrival of Mtb 
bacilli in the lung, it takes 7-9 days for the bacteria to be delivered to the draining 
lymph nodes and an additional 6-10 days for antigen-specific T cells to become 
activated and migrate to the primary site of infection [75]. A slow induction of the 
adaptive immune response allows Mtb infection to become well-established before 
effective bacterial elimination can occur [76]. Ineffective initiation of T cell responses 
may also be a product of the slow growth of the Mtb bacteria and of the relatively 
immune-privileged nature of the alveolar tissue [76]. Moreover, early induction of 
regulatory T cells (Tregs) with suppressive functions may be capable of delaying the 
priming of effector CD4+ and CD8+ T cells in the draining lymph nodes [77]. 
 8 
It has been shown that the development of effector T cell responses requires the 
dissemination of live bacteria or bacterial antigens presented by DCs [74, 78]. The 
function of CD4+ and CD8+ T cells in TB is to activate phagocyte killing of bacteria 
or to induce direct killing of Mtb-infected cells via expression of cytolytic effector 
molecules, but also to regulate the inflammatory environment to limit tissue damage 
[79, 80]. The major effector mechanism of cell-mediated immunity is the activation of 
infected macrophages by interferon-γ (IFN-γ) produced by CD4+ T cells [81]. The 
production of IFN-γ is regulated by IL-12, which is released by activated DCs as well 
as macrophages. IFN-γ cooperates with TNF-α to activate microbicidal mechanisms in 
macrophages that are responsible for the control and elimination of intracellular Mtb 
[82]. Moreover, cellular immunity involves killing of Mtb-infected macrophages by 
CD8+ cytolytic T cells (CTLs) expressing granule-associated effector molecules [82]. 
Induction of an effective adaptive immune response typically leads to Mtb containment 
inside highly organized granulomatous lesions.  
The importance of CD4+ T cells as the primary mediators of anti-TB immunity in 
humans was demonstrated by the observation that virus-mediated loss of CD4+ T cells 
in HIV-infected patients increased the susceptibility to TB [83]. Moreover, inherited 
deficiencies in the IFN-γ-receptor have been identified in humans that result in lack of 
IFN-γ signaling, which leads to a severely enhanced susceptibility to infection with 
mycobacteria of low-grade virulence [82].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Cellular immune responses in human TB. Mtb bacilli (red rods) primarily persist in 
the phagosomal system of infected macrophages. Activated macrophages try to combat the 
infection through the production of antimicrobial compounds but also through activation of 
Mtb-specific T cells. APCs such as macrophages and DCs take up the bacteria and present 
peptide and/or lipid antigens to CD8+ and CD4+ T cells as well as non-conventional T cells. 
While CD8+ T cells differentiate into CTLs, CD4+ T cells differentiate into cytokine-producing 
Th1, Th17 (T effectors), Th2 cells or immunosuppressive Treg cells. Fine-tuned interactions 
between pro- and anti-inflammatory responses determine the outcome of TB infection. 
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2.4 TB GRANULOMA: THE HALLMARK OF TB DISEASE 
A consequence of chronic inflammation and a typical hallmark of TB disease is 
formation of granulomas at the site of Mtb infection (Figure 4). Early granuloma 
formation is dictated by Mtb-infected macrophages that cluster together to form the 
core of the granuloma. Continuous activation of macrophages induces the cells to 
adhere closely together, assuming an epithelioid shape and sometimes fusing to form 
multinucleated giant cells (MGC) that are also called Langhans giant cells [84]. Apart 
from the macrophage populations, the granuloma mostly contains other immune cells 
such as different T cell subsets, B cells, neutrophils and DCs surrounded by an outer 
sheet of fibroblasts [84, 85]. In human TB, the immune reactivity present in the 
infected tissue will ultimately result in extensive cell death, detected as characteristic 
caseous necrosis in the center of the granuloma. Caseous granulomas are typical for 
human TB, but also other types of granulomas can be seen including non-necrotic 
granulomas, necrotic granulomas with neutrophils as well as fibrotic granulomas [86, 
87]. Typically, Mtb bacilli are released from dying cells into the caseous necrotic 
material of the granuloma where the bacteria can thrive and persist in an extracellular 
phase [87]. When liquefied granulomas burst into the bronchial system, extracellular 
Mtb bacilli can spread via aerosols expelled from the respiratory tract.  
 
 
Figure 4. Epithelioid TB granuloma in a human lymph node. EC=epithelioid cells; 
LY=lymphocytes; PL=plasma cell; FM=foamy macrophages; NE=necrosis. 
 
One of the most important factors required for control of TB infection is a balance 
between the pro-inflammatory and anti-inflammatory cytokines that are produced to 
reduce bacterial proliferation but also to reduce tissue damage. Here, TNF-α and IFN-
γ have been shown to be particularly important to promote the formation and function 
of the granuloma [88]. While IFN-γ has an essential role in activation of macrophages 
and T cells, TNF-α has a major role in the recruitment of different immune cell 
subsets to the granuloma [89]. The critical role of TNF-α in granuloma formation is 
demonstrated by the findings that the expression of chemokines is deregulated in 
TNF-α-deficient mice, which result in impaired recruitment of macrophages and T 
cells into the granuloma [89]. Although the granuloma provides an immunological 
microenvironment in which the infection can be controlled, some reports suggest that 
early granuloma formation may also function as a protective shelter for bacterial 
replication that can support bacterial dissemination [90, 91]. 
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2.4.1 Cell types in the TB granuloma 
Among the numerous cell types and inflammatory mediators involved in TB, the 
macrophage is the key host cell involved in granuloma formation and control of 
intracellular Mtb replication [86]. Mtb-infected macrophages recruit uninfected 
macrophages and other immune cells of both myeloid and lymphoid origin to 
ultimately form a productive granuloma [92-94]. 
 
2.4.1.1 Cells of myeloid origin in TB 
Macrophages: After initial infection of alveolar macrophages in the lung, monocytes 
migrate to the site of Mtb infection from the blood. Monocytes can differentiate into 
tissue macrophages that participate in the immune response against Mtb. Most of the 
macrophages involved in granuloma formation are the epithelioid cells, which are 
activated macrophages with abundant cytoplasm [88]. Recently, M1 and M2 
polarization of macrophages have been used to describe the two major and opposing 
activities of macrophages [95]. The M1 subset is classically activated macrophages 
with powerful bactericidal properties that are induced by Th1 cytokines (i.e. IFN-γ). 
M1 express inducible nitric oxide synthase (iNOS), which is an enzyme that catalyzes 
the synthesis of the potent antimicrobial compound nitric oxide (NO). Thus, the 
production of iNOS is strongly induced by IFN-γ. Conversely, the M2 subset is 
alternatively activated macrophages with anti-inflammatory properties that are induced 
by Th2 cytokines (i.e. IL-4, IL-13). M2 express Arginase type 1 (Arg-1), which is an 
enzyme that competes with iNOS for the use of arginine as a substrate [96]. 
Importantly, while iNOS use arginine as a substrate to generate toxic NO, Arg-1 use 
arginine as a substrate to generate ornithine. Ornithine promotes collagen deposition 
and contributes to the formation of epithelioid granulomas and tissue fibrosis. Thus, M2 
activation allows the bacteria to survive in infected macrophages partly by preventing 
NO synthesis. M2 also produce anti-inflammatory cytokines including IL-10 and 
transforming growth factor-β (TGF-β) that could further suppress a bactericidal state of 
the macrophage. TLR signaling triggered by mycobacteria could induce the production 
of Arg-1 via IL-10, IL-6 and granulocyte colony stimulating factor (G-CSF) and 
inhibition of Arg-1 expression has been shown to be beneficial for host survival [97, 
98]. The ratio between M1 and M2 macrophages in the granuloma are probably an 
important determinant for the outcome of TB infection, although the presence of both 
subsets may be required to maintain a balance between pro- and anti-inflammatory 
responses in the local environment.  
 
Multinucleated giant cells (MGCs): Chronically activated macrophages may also 
fuse to generate MGCs, which are characteristic of human TB (Figure 5). The cell-cell 
fusion process could be triggered by mycobacterial lipomannan in a TLR2-dependent 
manner [99] or by IL-4 in a STAT6-dependent manner [100]. MGCs may displace the 
normal tissue and release high concentrations of lytic enzymes, which destroy the 
surrounding tissue. The functional significance of MGCs during granulomatous 
inflammation remains to be determined. MGCs may lose their ability to mediate 
bacterial uptake due to decreased expression of phagocytic receptors such as the 
mannose receptor and CD11b [101] . However, MGCs seem to have retained the ability 
to present antigens and may therefore have a function in T cell priming [101].  
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Figure 5. Modified macrophages in TB. Continuous activation of macrophages induces the 
cells to adhere closely together, assuming an epithelioid shape and sometimes fusing to form 
multinucleated giant cells (MGC) that are called Langhans giant cells. 
Dendritic cells (DCs): DCs do not become productively infected with Mtb, but keep 
the bacteria in a non-replicating state [102]. Moreover, DCs are not very effective at 
killing Mtb [103] but these cells are more important in presentation of Mtb-antigens 
and triggering of specific T cell responses. Thus, DCs containing live mycobacteria 
could stimulate T cells but may also be used by pathogens as a vehicle for more 
efficient spreading. DCs present peptide and lipid antigens to T cells in the context of 
MHCII and CD1molecules, respectively. However, Mtb-induced DC maturation may 
lead to an uncoordinated presentation of primarily peptide antigens that may affect 
subsequent T cell activation [104]. There is also evidence that Mtb could inhibit 
MHCII antigen presentation by DCs without reducing surface expression of MHCII 
[105]. It is well-known that DCs have an important function in cross-presentation of 
Mtb-antigens as DCs can engulf apoptotic vesicles from Mtb-infected cells to prime T 
cells [106]. Importantly, IL-12 production by DCs is pivotal in the induction of IFN-γ 
and a Th1-mediated immune response that is required for immune protection in TB 
[107]. Mtb infection may fail to induce effective production of IL-12 by DCs, which 
could further subvert the induction of a proper Th1 response [103]. Even if DCs are 
present in chronic granulomatous lesions in the lungs, these cells have down-regulated 
MHCII and co-stimulatory molecules and consequently DCs isolated from the 
granulomas fail to induce proper activation of Mtb-specific CD4+ T cells [108, 109].   
 
Neutrophils: Neutrophils have been described as the first line of defense against Mtb. 
Initial interactions between Mtb and potently bactericidal neutrophils results in rapid 
apoptosis of the neutrophils that could prevent proper elimination of mycobacteria 
[110]. These cells can become infected  and are directly activated by Mtb products, 
such as LAM [111]. Neutrophils assist in killing of bacteria, primarily via production of 
reactive oxygen species, although virulent Mtb has evolved mechanisms to escape 
oxidative killing [112]. Neutrophils also initiate the inflammatory process through the 
secretion of chemokines, such as CXCL8 in order to recruit leukocytes and also 
organize early granuloma formation through the secretion of CXCR3-signaling 
chemokines [111, 113]. Recently, it has also been found that neutrophils exert early 
protection in the TB granuloma by oxidative killing of mycobacteria phagocytosed 
from dying Mtb-infected macrophages [114]. Neutrophils can take up mycobacteria 
and cluster with human DCs to promote DC activation with less IL-10 and better 
presentation compared to mycobacteria and DCs alone [115]. 
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2.4.1.2 Cells of lymphoid origin in TB 
CD4+ T helper 1 (Th1) cells: The essential role of CD4+ T cells in the control of 
mycobacterial infections has been highlighted in many studies [81, 116, 117]. 
Particularly, Th1 cells have a key function in protection against intracellular 
pathogens, including mycobacteria [117]. Th1 cells typically produce IFN-γ and 
TNF-α which synergize to activate microbicidal effector mechanisms in human 
macrophages [118]. In addition, IL-2 is produced that supports the proliferation and 
clonal expansion of antigen-specific T cells. A Th1 cytokine profile is required for 
proper activation and differentiation of CD8+ CTLs that participate in killing of Mtb-
infected cells [80]. Deficiencies in the Th1 pathway, that occur either as a 
consequence of HIV infection, cancer, immunosuppressive drugs or genetic defects, 
greatly increase the susceptibility to mycobacterial diseases [119]. APCs stimulate 
CD4+ T cells via T cell receptor engagement and co-stimulatory molecules including 
CD40-CD40L and CD80/CD86-CD28 [120, 121]. Properly activated APCs produce 
IL-12, which is a crucial cytokine that promotes Th1 polarization including elevated 
production of IFN-γ. The early CD4+ T cell-dependent burst of IFN-γ production 
seems to be critical for the effective control of TB infection [81]. In addition, 
polyfunctional Mtb-speciﬁc CD4+ T cells secreting combinations of IFN-γ/TNF-α or 
IFN-γ/IL-2 have been detected in patients with TB/HIV co-infection [122]. Here, 
effective anti-TB treatment leads to a shift from IFN-γ single positive CD4+ T cells to 
predominantly IFN-γ+/IL-2+ double-positive T cells [122], which suggests that 
polyfunctional CD4+ T cells may be involved in immune protection in TB. 
 
CD4+ T helper 2 (Th2) cells: While a Th1 response is required for immune control in 
TB, active TB disease has been associated with increased activation of Th2 cells in 
vivo [123]. Th2 cells typically produce IL-4, IL-5 and IL-13, which contribute to 
initiation of a humoral immune response. However, since Mtb is mostly an 
intracellular bacterium, antibody-mediated immunity may not provide protective 
immunity in TB [124] and a pathological role of a Th2 type response involving IL-4 
has previously been described [125]. Thus, increasing evidence supports the notion 
that Th2 polarization could affect disease susceptibility in TB [125-127]. A 100-fold 
increase of IL-13 and IL-4 has been reported in patients with active TB compared to 
age- and gender-matched controls [128].  It has also been demonstrated that 
progressive TB disease might be due to preexisting Th2-like activity that could 
induce toxicity of TNF-α and/or impair bactericidal functions [129]. Importantly, 
progressive TB disease may not be solely associated to the absence of a Th1 
response, but may rather be caused by co-existing Th1/Th2 or excessive Th2 
immunity [123]. 
 
CD4+T helper17 (Th17) cells: Th17 cells are pro-inflammatory cells that mediate 
antimicrobial immunity against bacteria and fungi [130], particularly at mucosal 
surfaces. Studies have shown that Th17 cells emerge in the early phase of adaptive 
immunity and contribute to host defense against intracellular pathogens, including 
Mtb [131]. Th17 cells produce IL-17, IL-21, IL-22 and IL-23 and in addition to the 
classical Th1 response, a Th17 response is considered to be protective in 
mycobacterial infection. Th17 cells can trigger the production of chemokines 
(CXCL9, CXCL10 and CXCL11) that recruit IFN-γ producing CD4+ T cells to the 
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site of Mtb infection in the lung, which result in restriction of bacterial growth [131]. 
Th17 cells can also regulate the production of antimicrobial peptides [132] and has 
been shown to be essential in the formation of mature TB granulomas in the lung 
[133]. BCG vaccination induce both Th1 and Th17 cells [134] while Th17 cells are 
reduced in the peripheral circulation of active TB patients [135]. Whether these cells 
are ultimately necessary for protection or contribute to disease pathology is not clear. 
 
Regulatory T cells (Tregs): Natural Tregs constitute about 5% of peripheral T cells 
and constitutively express CD25, the transcription factor fork head box P3 (FoxP3) 
and the T cell inhibitory receptors, Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) and 
the Glucocorticoid-Induced TNFR family related gene (GITR) [136]. Inducible Tregs 
can also develop from conventional CD4+ T cells that are exposed to immuno-
regulatory cytokines or other deactivating signals [137]. The CD4+CD25+FoxP3+ 
Treg compartment has been shown to be expanded in patients with active TB [138] 
and Tregs also expand in the lung during experimental Mtb infection, which interfere 
with bacterial control [139]. CD4+Foxp3+ Tregs are present in the granuloma of 
humans, non-human primates and mice [139-141]. The immunosuppressive functions 
of natural and induced Tregs are known to be dependent on negative signals induced 
by CTLA-4, GITR or Programmed cell Death-1 Ligand (PDL1), but also on soluble 
factors such as IL-10 and TGF-β [142]. Expansion and accumulation of Tregs has 
been shown to decrease Th1 cell responses in patients with TB [143]. It has also been 
shown that the immunosuppressive cytokines that impair immunity to Mtb can be 
produced by both Tregs and anti-inflammatory M2 macrophages [144, 145].  
Excess numbers of Mtb-specific Tregs may restrict and delay T cell effector 
responses that is detected in TB [146]. This includes delays in priming, expansion and 
mobilization of both CD4+ and CD8+ effector T cells [77], which allows enhanced 
Mtb growth. Tregs also counteract Th17 cells, thus inhibiting the early recruitment of 
IFN-γ-producing CD4+ T cells to the site of infection [131]. Immature DCs, tolerizing 
DCs and anti-inflammatory macrophages that are targeted by Mtb have all been 
shown to be capable of inducing Tregs [147, 148]. Although enhanced Treg responses 
are generally considered detrimental in chronic infections including TB, these cells 
may also have a function to prevent pathology in persistent infections [86]. 
 
CD8+ T cells: Mtb-specific CD8+ T cells have been described in human TB [149] as a 
subset of T cells that are required to obtain maximum control in TB infection [150]. 
CD8+ CTLs are specialized to kill Mtb-infected target cells by  the release of granules 
containing cytolytic and bactericidal effector molecules, but can also be activated to 
produce Th1 cytokines that contribute to immune protection [146]. Thus, there is 
evidence that CD8+ T cells participate in the control of Mtb infection by lysis of Mtb-
infected macrophages combined with killing of intracellular bacteria [151] and also 
by the expression of effector cytokines [152, 153]. While CD8+ CTLs possess potent 
anti-mycobacterial activity via granule-mediated cytotoxicity [154], death receptor-
ligand induced apoptosis may be less efficient in killing intracellular Mtb [155]. Mtb-
specific CTLs have been found in humans [151] and shown to kill Mtb-infected cells 
using the pore-forming protein perforin in cooperation with the antimicrobial peptide 
granulysin [156]. Important evidence has been provided that Mtb-reactive CD8+ 
effector memory T cells expressing high levels of perforin and granulysin, can mediate 
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antimicrobial activity in human TB [157].  Reduced numbers of these effector T cells 
were detected in patients with rheumatoid arthritis after treatment with anti-TNF-α 
inhibitors, which resulted in a significantly enhanced susceptibility of the patients to 
develop active TB [157].  
Polyfunctional  Mtb-specific CD8+ T cells have also been described. The peripheral 
frequency of IFN-γ+/IL-2+ double-positive CD8+ T cells has been shown to correlate 
with host protection and a curative response to anti-TB treatment [149]. In contrast, a 
regulatory function of CD8+ T cells have been found in the TB granuloma where 
activated CD8+ T cells produced the chemokine XCL1 (lymphotactin), which 
negatively regulates IFN-γ production by CD4+ T cells [158]. In addition, analyses of 
CD8+ T cell repertoires in children with TB have identified clonal expansion of 
terminally differentiated CD8+ effector T cells in severe forms of disease [159]. 
Hence, CD8+ T cells may also serve as targets of immune evasion by Mtb. 
 
B cells: Humoral immune responses are vital for protective immunity to many 
pathogens and thus antibody production by B cells is one of the most important 
effector functions of these cells. However, B cells also carry out a variety of other 
effector and regulatory functions during the course of an immune response [160]. B 
cells mediate protection from pathogens via antigen presentation, co-stimulation and 
antibody secretion, but also by producing cytokines that regulate the quality and 
magnitude of humoral as well as T cell responses [161]. It is becoming clear that the 
different effector functions of B cells are tightly controlled and that there are 
functionally and phenotypically distinct effector and regulatory B cell subsets that can 
be sub-divided also based on their cytokine profile [160]. The functional relevance of 
the different cytokine profiles is illustrated by the ability of distinct effector B cell 
subsets to polarize the development of T cells along the Th1 or Th2 lineage [162, 
163], via production of IFN-γ and IL-4 [162]. Lately, it has also become evident that 
regulatory B cells producing IL-10 can maintain FoxP3+ Tregs and limit Th1 and 
Th17 responses in healthy individuals, but not in patients with an autoimmune 
rheumatoid arthritis [164]. Contrary, patients with active TB were found to have 
significantly higher frequencies of regulatory B cells with stronger suppressive activity 
compared to healthy controls [165]. Interestingly, the frequency of regulatory B cells in 
peripheral blood was inversely correlated with that of Th17 cells in these TB patients 
[165].  
While a protective immune response in TB infection is mostly based on cellular 
immunity, the role of B cell mediated immunity in TB remains controversial [166, 
167]. B cells have been shown to have a significant impact on the inflammatory 
response and disease outcome upon aerosol challenge with Mtb in experimental 
animal models [168]. B cells have also been shown to be present in granulomatous 
TB lesions in the lung [85, 169, 170], which may indicate that B cells are involved in 
the organization and development of the TB granuloma [169]. Thus, B cells may 
potentially use their diverse functions to regulate other immune cells present in the 
granulomas including macrophages and T cells [86].  
Since Mtb is an intracellular bacterium, the role of antibodies in TB remains 
debatable. However, extracellular Mtb bacilli and bacterial products are released 
during progressive TB disease, which will result in significant amounts of bacterial 
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antigens in the local tissue environment that will leak out into the peripheral 
circulation. This will promote activation and differentiation of plasma B cells and 
some studies have shown a protective function of antibodies in Mtb infection [171]. 
Several mechanisms have been proposed for this protection including antibody-
mediated inhibition of Mtb attachment to human macrophages [172], enhancement of 
phagolysosomal fusion inside Mtb-infected cells, neutralization of bacterial products 
and cellular- or complement-mediated bacterial lysis [173]. By virtue of their ability 
to produce antibodies, B cells are also essential to form immune complexes with 
potent immunoregulatory functions [174]. Here, ligation and activation of Fcγ 
receptors (FcγRs) on macrophages by immune complexes can have prominent 
immunological effects including induction of phagocytosis [175]. On the contrary, the 
ligation of monocyte or macrophage Fcγ receptors by IgG immune complexes lead to 
an increased production of IL-10 [175] and promote a shift of Th1 to Th2 responses, 
which result in an increased infectious output in parasite infected cells [176]. This 
intrinsic antibody-dependent enhancement (ADE) facilitates microbial entry into host 
cells that could modulate the severity of infectious diseases [176]. Accordingly, the 
ligation of FcγRs by antibody-coated Leishmania resulted in increased IL-10 and 
decreased IL-12 production by macrophages, thus enhancing leishmanial growth in 
macrophages [176]. Immune complexes are known to exist in Mtb infection [177, 
178], but whether ADE is applicable in human TB remains to be determined. 
 
Other T cells subset: Apart from the interaction with conventional lymphocytes of 
the adaptive immune system, mycobacteria can interact with human innate lymphoid 
cells and modulate their function. Gamma-delta T cells (γδ T cells) are non-
conventional T cells that can perform a vast array of immune effector functions and 
appear to play important roles in antimicrobial immunity as well as in chronic 
inflammatory reactions [179]. The early source of IL-17 is mostly from γδ T cells, 
which bridge innate and adaptive immunity and play an essential role in early host 
defense in TB [180]. The γδ T cell compartment has been shown to expand after 
mycobacterial infection in humans [181]. This compartment also expands rapidly to 
recall responses, to Mtb antigens and live infection, in a similar manner to memory 
cells [181, 182]. Human DCs infected with M. bovis BCG activate γδ T cells to kill 
mycobacteria-infected primary macrophages but not infected DCs by a perforin-
mediated mechanism [183].  
Other studies have identified non-classical Mtb-reactive T cell subsets that are 
enriched in the lung mucosa. These T cell subsets recognize antigen presented by 
non-classical MHC molecules [146]. The best known are CD1 restricted T cells that 
recognize mycobacterial lipids [184], although their role in protective immunity in 
TB remains incompletely defined. Another recently discovered T cell subset is 
mucosa-associated invariant T (MAIT) cells, which also recognize antigen in the 
context of the MHC class-Ib molecule MR1 (MHC class I related) expressed on 
phagocytes and epithelial cells [185]. MAIT cells are enriched in the human lung and 
recognize epithelial cells infected by a broad spectrum of bacterial species including 
Mtb [186]. MAIT cells respond rapidly, are cytolytic, secrete multiple cytokines 
(IFN-γ and IL-4) and appear to be important effector cells in mucosal immunity. 
[146]. The precise ligands presented by MR1 remain unidentified, but may involve 
vitamin B metabolites that are produced by bacteria [187]. 
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Natural killer (NK) cells: It is well-known that NK cells are important in the innate 
defense against pathogens [188]. Previous studies have demonstrated that human NK 
cells can recognize and lyse Mtb-infected macrophages using the NKp46 receptor 
[189]. In addition to the role of activated NK cells in granule-mediated killing of 
infected cells, these cells also produce significant amounts of cytokines. In the 
presence of IL-15 and IL-23, CD3-CD56+ NK cells produced vast amounts of IL-22 
when exposed to autologous monocytes and gamma-irradiated Mtb. Addition of 
recombinant IL-22 to Mtb-infected macrophages enhanced phagolysosomal fusion and 
reduced growth of Mtb, suggesting that NK cells can contribute to immune defenses 
against Mtb through production of IL-22 [190]. 
 
Natural killer T (NKT) cells: NKT cells are known to play a protective role in the 
immune responses against a variety of infectious pathogens [191]. The proportion of 
NKT cell and their proliferative responses were significantly lower in the peripheral 
blood of PTB and EPTB patients compared to latent TB subjects and healthy controls 
[191]. A poor NKT cell response in Mtb-infected patients was found to be due to 
increased NKT cell apoptosis, reduced CD1d expression and an elevated expression of 
the inhibitory receptor PD-1 on NKT cells [191]. 
 
2.4.2 Immune mediators in TB  
A network of different immune mediators that are produced by the different cells 
involved in TB will ultimately determine the outcome of Mtb infection. Both poor 
and exaggerated inflammatory responses will lead to disease. This fine balance 
requires bacterial orchestration of both innate and adaptive immunity [87]. The 
cytokine balance during mycobacterial infection is the key to control bacterial growth 
and to maintain tissue function [192]. In addition to the role of cytokines in the 
formation and stability of the granuloma, the presence of chemokines is crucial for 
the recruitment of inflammatory cells to form granulomas [193].  
 
2.4.2.1 Pro-inflammatory and effector cytokines in TB 
TNF-α: TNF-α is produced by a variety of cells including macrophages, lymphocytes, 
neutrophils, mast cells and endothelial cells. Several important functions have been 
attributed to TNF-α [194, 195], including control of bacterial replication in the host by 
activation of antimicrobial effector functions in macrophages and T cells and also by 
organization of granuloma formation [196, 197]. There is experimental data indicating 
that TNF-α promotes autophagy but also phagolysosomal maturation in an IFN-γ-
dependent manner [198-200]. In addition, TNF-α induces early production of 
chemokines by macrophages, which initiate recruitment of immune cells to the site of 
Mtb infection. Accordingly, TNF-α-deficient mice produce reduced levels of 
chemokines that result in defective granuloma formation [89]. Likewise, blockade of 
TNF-α during the chronic phase of experimental Mtb infection leads to breakdown of 
the granuloma and an enhanced pro-inflammatory response, which suggest that TNF-α 
may also exert an anti-inflammatory effect on certain inflammatory mediators [201]. 
Intricate regulation of the timing, site and extent of TNF-α production is required in 
response to mycobacterial infection, as this fine-tuning will have a significant influence 
on the net effect of bacterial control [87]. Too little TNF-α will fail to induce proper TB 
immunity and distort granuloma formation while too much TNF-α will exacerbate 
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tissue damage and compromise lung function. The importance of TNF-α in human TB 
was confirmed by the finding that TNF-antagonists increased the risk of active TB 4-
10-fold among patients with rheumatoid arthritis [202-204]. The TB disease pattern in 
these patients is characterized by a high rate of extrapulmonary (56-62%) and 
disseminated TB disease (24-28%) [205]. Previous reports demonstrate that anti-TNF 
treatment resulted in a decreased frequency of a subpopulation of memory CD4+ T cells 
[206] and also of CD8+ effector memory T cells [157], which confirm that this 
treatment has severe effects also on Mtb-specific T cell responses.  
 
IL-1β: IL-1β is produced by monocytes, macrophages and DCs [207]. Expression of 
this highly pro-inflammatory cytokine is tightly controlled through the combination of 
two distinct triggers: Signal 1 typically involves activation via a TLR ligand while 
signal 2 involves the assembly of a protein complex known as the inflammasome that 
activates caspase-1, which cleaves the proform of IL-1β into the mature form [208, 
209]. Infection with both Mtb and M. bovis BCG induces IL-1β mRNA in human 
macrophages but only virulent Mtb can activate type I IFN signaling and selectively 
limit the production of IL-1β [210]. In addition, decreased caspase-1-dependent IL-1β 
activation was seen in the BCG-infected macrophages [210]. Mtb can also limit IL-1β 
expression by inducing Zn2+ metalloproteases, which inhibits the inflammasome [211]. 
Whereas IL-1β is an important mediator of the inflammatory response in TB, high 
levels of IL-1β may also be exploited by Mtb to cause severe inflammation and tissue 
destruction. Here, both IL-1β and TNF-α can induce the expression of the protease, 
matrix metalloproteinase (MMP)-1, as shown in lung fibroblasts in vitro as well as in 
human TB granulomas [212]. MMP-1 transgenic mice develop more severe alveolar 
destruction and collagen breakdown during Mtb infection, which suggest that MMP-1 
promotes tissue destruction in TB [213]. MMP-1 function can be regulated by specific 
inhibitors that are down-regulated by Mtb [212, 214]. Accordingly, high levels of 
MMP-1 and low levels of inhibitors have been found in the bronchoalveolar lavage 
(BAL) of TB patients [213].  
 
IL-6: IL-6 is secreted by different cell types including activated T cells, macrophages, 
fibroblasts and endothelial cells [215]. This is a cytokine with a wide variety of 
functions that can exert pro- or anti- inflammatory effects, but mostly IL-6 is critical for 
the development of an early inflammatory response [194]. IL-6 is also involved in 
hematopoiesis [216]. In addition, IL-6 and IL-12 are critical in the development of 
efficient anti-mycobacterial responses by T cells, as both IL-6 gene-disrupted mice and 
depletion of IL-6 and IL-12 with neutralizing antibody showed reduced antigen specific 
proliferation and IFN-γ secretion after vaccination with Mtb culture filtrate [217]. 
Although IL-6 may support IFN-γ production in the early phase of TB infection, IL-6 
does not seem to be essential for the development of protective immunity in TB [218].  
 
IL-12: The production of IL-12 by DCs and macrophages is essential for the 
development of host Th1 immunity and resistance against intracellular pathogens [219]. 
This is primarily accomplished by IL-12-mediated induction of IFN-γ production in 
NK, NKT and T cells. Thus, IL-12 promotes the differentiation of naive CD4+ T cells 
into Th1 cells that produce IFN-γ and aid cell-mediated immunity [220]. IL-12-
deficiency strongly increases the susceptibility to mycobacterial disease in humans, 
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which underlines the importance of IL-12 to trigger Th1 immunity [221]. IL-12 is 
rapidly produced by mature DCs after interaction of Mtb with TLRs on the DC. Studies 
have suggested that induction of IL-12 production is dependent on TLR9 on DCs and 
TLR2 on macrophages [221]. It has also been found that both human and murine 
macrophages release significantly lower amounts of IL-12 than DCs in response to Mtb 
infection, showing that DCs are better IL-12-producers compared to macrophages [222, 
223]. Previously, it was shown that the Mtb cell wall component ManLAM were able 
to inhibit TLR-induced IL-12 production by human DCs [224], which may prevent 
proper DC maturation and T cell activation. 
 
IFN-γ: IFN-γ, produced by activated T cells, NK and NKT cells, is a key effector 
cytokine that promotes the activation of phagocytes, cellular proliferation, cell adhesion 
and apoptosis [225]. The function of IFN-γ in response to pathogens has been 
extensively studied and it has been shown to be critical in the regulation of cellular 
immune responses in mycobacterial disease [226]. IFN-γ activates macrophages, and 
enables them to overcome Mtb-induced arrest of phagosomal maturation and enhance 
MHCII-restricted antigen presentation [227]. In addition, IFN-γ induces autophagy in 
infected macrophages enabling them to inhibit intracellular survival of Mtb [228]. In 
macrophages, IFN-γ also induces the respiratory burst pathway that contributes to the 
production of RNIs and oxygen intermediates (ROIs) [226]. The production of large 
amounts of ROIs and NO by innate immune cells is considered to be one of the most 
important effects of IFN-γ in the early immune defense against TB. CD4+ T cells play a 
central role in containment of Mtb infection by secreting IFN-γ that will activate 
macrophages as well as Mtb-specific CTLs [229]. Accordingly, there is an enhanced 
susceptibility to mycobacterial infection in IFN-γ-knockout mice [230]. IFN-γ-deficient 
mice also fail to develop granulomas following aerosol infection with Mtb and show  
significant impairment of macrophage activation [231]. The importance of IFN-γ in 
human TB has been discovered in patients with severe mycobacterial infections, who 
had a mutation in the gene for IFN-γ receptor 1 that resulted in reduced macrophage 
activation [232]. Together, these studies confirm an important role of IFN-γ in response 
to intracellular pathogens such as mycobacteria. 
 
IL-17: IL-17 is primarily produced by γδ T cells and CD4+ T cells and has a function 
as a pro-inflammatory cytokine that supports the recruitment of effector cells such as 
neutrophils and activated T cells to disease sites [233]. Thus, the role of IL-17 in the 
development of antimicrobial responses, chemokine production and recruitment of 
inflammatory cells has been described in several studies [133, 234-236]. Particularly 
the IL-23/IL-17 pathway has been demonstrated to be involved in the development of 
protective and regulatory immune responses in mice and humans infected with Mtb 
[131, 237]. Here, IL-23 may not be a determining factor for the early control of Mtb 
infection but is required for the development and maintenance of Th17 responses [236]. 
It has been found that IL-17 participates in the activation of macrophages and IL-17-
producing CD4+ T cells are present in mycobacterial granulomas [238].  
 
IL-4: The Th2 cytokines, IL-4 and IL-13, are produced by Th2 cells and basophils 
[239, 240]. Both IL-4 and IL-13 are typically involved in antibody-mediated humoral 
immunity with limited protective effects in intracellular Mtb infection [125, 241]. IL-4 
is a Th2 signature cytokine and is implicated in the activation of anti-inflammatory type 
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of macrophages (M2) through IL-4R signaling [242]. Both IL-4 and IL-13 have been 
shown to be detrimental in the control of intracellular Mtb infection, as these cytokines 
suppress IFN-γ production and IFN-γ-mediated effects [243]. Furthermore, IL-4 can 
inhibit autophagy, which is known as a physiological mechanism to enhance 
intracellular degradation of dysfunctional cell components including intracellular 
microbes as Mtb [126]. IL-4 and IL-13 also induce in vitro expansion of antigen-
specific FoxP3+ Treg cells from both human and mouse cells [244]. Moreover, IL-4 has 
been shown to antagonize host defenses and lead to tissue necrosis in patients with TB 
[245]. Increased Th2 responses in the lung augment immunopathology by induction of 
pulmonary fibrosis and cavitation, which compromise lung function in TB patients 
[125, 245]. 
 
2.4.2.2 Chemokines in TB 
CC and CXC chemokines: Chemokines produced during mycobacterial infections 
augment the host’s innate resistance while shaping the ultimate adaptive immune 
response [246]. Chemokines are small (around 8-14 kDa) cytokines that are grouped 
as CC and CXC chemokines, depending on the amino acid present between the first 
two out of four cysteine residues [247]. Similar to cytokines, these small signaling 
molecules play a central role in the orchestration of tissue homeostasis and 
inflammation and deregulated chemokine production have been implicated in several 
human infections [248, 249]. Chemokines play an important role in leukocyte 
recruitment to the site of inflammation [250, 251] and also regulate cell activation, 
migration and survival [252-254]. The contribution of chemokines in the control of 
Mtb infection has been described by several in vitro and in vivo studies [255-257]. 
Chemokines promote migration of monocytes, DCs, activated macrophages, 
neutrophils and T lymphocytes to bronchoalveolar spaces during PTB [258] and play 
a significant role in the recruitment of effector T cells to the site of Mtb infection 
[259].  
CC chemokines are a sub-group of chemokines that include 27 members. In addition 
to their well-characterized roles in the regulation of inflammation and immune 
homeostasis, some members of this chemokine family such as CCL2 have been 
associated with increased susceptibility to PTB [260]. High concentrations of CCL2 
have been shown to inhibit production of IL-12 in cultures of Mtb-stimulated 
monocytes, which may increase the likelihood of the infection to progress to active 
PTB [261]. CCL5 is a chemokine produced by a variety of cells including 
macrophages, fibroblasts, eosinophils, endothelial cells and platelets. CCL5 exerts 
chemotactic activity on NK cells, T cells, DCs and macrophages to inflamed or 
infected tissues [262]. The expression and functional activities of CCL5 have been 
studied in experimental models of type 1 and type 2 granulomas, elicited by M. bovis 
and schistosoma infection, respectively. These results demonstrated higher levels of 
CCL5 in type 1 lesions [263]. Consequently, the recruitment of APCs and T cells and 
also the formation of granulomas induced by Mtb, have been shown to be reduced in 
CCL5 knockout mice [264]. CCL5 is especially important in the early responses to 
Mtb due to its role in recruitment of IFN-γ-producing T cells to form lymphocyte 
enriched granulomas at the site of infection [264].  
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CXC chemokines are a sub-group of chemokines that includes 17 members. M. bovis 
BCG-infected human epithelial cells can play an active role in local inflammatory 
immune responses via the secretion of CXC chemokines [265]. It has also been 
shown that neutralization of TNF-α in Mtb-infected macrophages resulted in a 
reduction of many inflammatory chemokines such as CCL5, CXCL9 and CXCL10, 
both in vitro and in vivo [266]. CXCL8 is a proinflammatory chemokine with the 
ability to recruit neutrophils and T cells in response to a variety of stimuli [267]. It has 
been shown that IL-4 can selectively reduce the levels of CXCL8, while it did not 
have a significant effect on CXCL10 levels. This down-regulation of CXCL8 
secretion may be important to prevent pathological inflammation in human TB, but 
may simultaneously reduce imperative cell-mediated immune responses, since CXCL8 
is required to induce neutrophil and T cell migration [265]. CXCL9 and CXCL10 are 
induced by IFN-γ during infection, injury or inflammation, to participate in leucocyte 
trafficking of mainly activated CD4+ Th1 cells, CD8+ T cells and NK cells [268]. 
CXCL10 secretion is induced in Mtb-stimulated macrophages [269] and attracts T 
cells but not neutrophils [270].  
  
2.4.2.3 Cytolytic and antimicrobial effector molecules in TB  
Reactive nitrogen species: ROS and RNI are produced by macrophages and 
neutrophils and effectively kill various bacteria [271]. Of greater importance in TB is 
RNI and particularly NO, which is produced upon activation of iNOS using L-arginine 
as a substrate [272]. In the mouse model of Mtb infection, it has been confirmed that 
NO is essential in TB control by killing of Mtb in mononuclear phagocytes [63]. In 
iNOS-deficient mice, TB infection has a rapid progression and results in a higher rate 
of mortality compared to wild-type mice [273, 274]. However, it has been much more 
difficult to confirm a role of NO in humans, partly because human macrophages cannot 
produce NO upon stimulation or  Mtb-infection in vitro [275]. However, both iNOS 
and the NO-metabolite nitrotyrosine, have been detected in situ in tissue from human 
TB granulomas [141], which may suggest that macrophages are activated to produce 
NO in vivo at the site of Mtb-infection. 
 
Cytolytic effector molecules: As described above, the granule-exocytosis pathway of 
cytolytic lymphocytes is crucial for immune surveillance and homeostasis in TB as 
well as other infectious and non-infectious diseases. Cytolytic granules typically 
contain cytolytic and antimicrobial proteins that execute the function of the CTL. Here, 
the membrolytic pore-forming protein perforin was originally purified from cytolytic 
granules and identified as a key effector molecule for T cell and NK cell mediated 
cytolysis [276]. Perforin is released, via the granule-exocytosis pathway, into the 
immunological synapse of the CTL and the target cell where it forms pores in the target 
cell membrane to trigger cell lysis [277-279]. In this process, other effector molecules 
including granzymes and granulysin may also be released from the lytic granules to 
enter specific target cells. Granzymes are serine proteases that cleave specific substrates 
in the cytosol to promote rapid and efficient apoptosis by various pathways [280, 281] 
Elevated levels of circulating extracellular granzymes A and B have been associated 
with various inflammatory diseases [282-284]. 
Perforin plays a major role in CTL function and the regulation of intracellular bacterial 
infections like TB [285, 286]. Consequently, patients with a deficiency in perforin 
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show impaired lymphocyte cytotoxicity [287]. Furthermore, perforin-deficient mice 
also show reduced killing of Mtb-infected target cells, which correlates with diminished 
protection [288]. Perforin-deficient mice also show defective granzyme-mediated 
cytotoxicity in both CTLs and NK cells [289, 290].    
The antimicrobial peptide granulysin is a human polypeptide that is constitutively 
expressed in NK cells and induced in CTLs upon activation [291] with activity against 
a broad range of microbes [292]. The lytic effect of granulysin towards mycobacteria 
was initially discovered to decrease the viability of intracellular Mtb in cooperation 
with perforin [156]. Granulysin is a small cationic molecule with the ability to interact 
with the negatively charged surface of the mycobacteria through ionic strength [156]. 
The bacterial membranes are disrupted upon leakage of fluids that will end in osmotic 
lysis of bacterial cells [293]. Granulysin can also lyse human cells through the 
mitochondrial pathway of apoptosis [294]. Reduced levels of granulysin have been 
shown to be associated with progression of clinical disease caused by both M. leprae 
[295] and Mtb [296]. The mycobactericidal activity of granulysin constitutes an 
attractive pathway of protective immunity in humans, which could be targeted by 
vaccination [297]. 
 
2.4.2.4 Negative regulators in TB 
Anti-inflammatory cytokines: IL-10 and TGF-β are immunoregulatory cytokines 
produced by macrophages and certain T cell subsets such as Tregs [146]. These 
cytokines are typically involved in the down-regulation of Th1 responses and IL-10 is a 
well-known antagonist of IFN-γ [298]. Similar to Th2 cytokines, IL-10 and TGF-β 
possess antagonistic effects on cellular immunity by inhibition of T cell proliferation, 
reduced production of IFN-γ and pro-inflammatory cytokines, reduced antigen 
presentation and reduced activation of bactericidal macrophages [299]. However, IL-10 
possesses a stimulatory capacity on Th2 cells and also promotes B cell maturation and 
antibody production [300]. Likewise, TGF-β is believed to be important for the 
differentiation of FoxP3+ Treg cells and Th17 cells [301]. Both IL-10 and TGF-b are 
known to be involved in the pathogenesis of active TB and transient overexpression has 
previously been observed in TB patients [302]. Together, TGF-β and IL-10 potentiate 
the down-modulatory effects on Mtb-induced T cell production of IFN-γ, and TGFβ 
enhances IL-10 production [303]. Mycobacterial components have also been shown to 
induce TGF-β production in peripheral blood monocytes from TB patients [304]. In 
addition, TGF-β supports the production and deposition of macrophage collagenases 
[299] and collagen matrix [305] that may alter tissue morphology and promote tissue 
fibrosis in Mtb-infected organs. 
 
Suppressors of cytokine signaling (SOCS): SOCS molecules act as feedback 
inhibitors induced by different stimuli including cytokines and TLR ligands [306]. The 
SOCS family comprises eight members and at least four of these, namely CISH, 
SOCS1, SOCS2, and SOCS3, are expressed in T cells [307]. The mycobacterial cell 
wall possesses a variety of lipopeptides and liposaccharides that act as TLR ligands. 
TLR engagement by these ligands during bacterial phagocytosis can lead to inhibition 
of cytokine synthesis [308] and decreased cytokine responsiveness through induction of 
SOCS [309]. Common cytokine receptors use the Janus kinase (JAK) and signal 
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transducers and activators of transcription (STAT) signaling pathway [310] that are 
regulated by several molecules including members of the SOCS family [307].  
Some of the SOCS molecules have been found to be raised in patients with active TB, 
which may indicate an important role of SOCS in the regulation of TB-specific 
immunity [311]. SOCS-mediated regulation of cytokine production may ultimately 
affect immune polarization and immune cell function. Mtb expresses different 
antigens with the ability to inhibit IL-12 secretion and induction of oxidative burst by 
inducing increased expression of SOCS1 [312]. SOCS1 could also regulate IFN-γ 
expression and function [313]. SOCS3 overexpression in mice has been shown to 
promote the generation of Th2 cells [314]. It has also been shown that SOCS3 seems 
to be preferentially expressed in Th2 cells [315] while SOCS3 overexpression inhibits 
differentiation of Th17 cells [316].  
 
2.5 TB DISEASE: CLINICAL FEATURES, DIAGNOSIS AND TREATMENT 
2.5.1 Common aspects of active TB disease 
Active TB is the common name for a broad spectrum of different forms of clinical TB 
disease described below. Even though lung or PTB is the most common form of 
disease, TB may affect any organ in the body and cause EPTB. Mtb bacilli may also 
escape from infected foci in the lung and enter the blood stream and cause miliary TB, 
which may develop into a fatal condition. The greatest risk for development of active 
disease is between 1-5 years after primary exposure to Mtb. The risk decreases for 
every year and on average the risk is 10% in a life-time for HIV-negative individuals. 
The risk of active disease is greatest in infants that are younger than 4 years and slowly 
declines from age 5-10 years. During adolescence, age 15-19 years, the risk rapidly 
increases with a second peak between the ages of 20-30 years [317]. Age-related 
differences in disease risk are accompanied by differences in the response to TB 
infection and clinical features of disease. In early childhood, disseminated forms of 
disease such as miliary TB and TB meningitis are common. With increasing age, these 
features become less common with a sudden shift in disease pathology observed during 
adolescence.  At this stage, the features of TB disease resemble the hallmark of adult 
disease including severe inflammation, tissue destruction and lung cavitation [317-
319]. Both ageing and HIV infection result in markedly reduced function of the 
immune system as does other types of immunosuppressive conditions or treatments 
such as poor nutrition, drug abuse, anti-TNF-α inhibitors, cancer, diabetes and smoking 
[320]. Similar to elderly people, HIV-infected patients tend to develop a more 
disseminated disease with less lung cavitation. The clinical symptoms of TB can be 
many but primarily include cough, chest pain, fever, weakness, chills, night sweats and 
weight loss. The infectiousness of a person with TB is a multifactorial event depending 
on the clinical form of TB, the bacterial load in the lungs, the environment in which the 
exposure occurs, duration of exposure, virulence of the Mtb strain and also the 
susceptibility of the person to whom the infection is spread to.  
 
2.5.2 Clinical forms of TB 
2.5.2.1 Pulmonary TB (PTB) 
PTB is the primary site of TB disease and represents the majority of all active TB cases 
reported annually. Cough is the most common clinical symptom of PTB and thus long-
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term cough over 3-4 week is strongly indicative of TB, especially in high-endemic 
countries. Early in the course of illness there may not be production of sputum, but after 
initiation of inflammation and tissue damage, sputum and sometimes bloody sputum is 
produced by the TB patient. Children do not produce sputum as they cannot cough with 
a force similar to adults, and therefore PTB in children is rarely infectious. Clinical 
symptoms of PTB are generally not specific enough to confirm an active TB diagnosis; 
while PTB nearly always causes abnormalities in the lung that could be detected with 
chest X-ray. These abnormalities could be visible as inflammatory infiltrates or small 
nodular lesions, but large cavities may also be detected in patients with an untreated 
progressive PTB. Lung cavitation is typically considered an open form of TB disease, 
which results in efficient transmission of Mtb to other people [321]. Cavitation is 
probably the effect of a robust immune response that lead to severe tissue destruction in 
the lung [321]. Thus, PTB can also be divided into sub-groups including non-cavitary 
and cavitary forms of PTB. PTB mostly occurs as a local infection where the disease is 
isolated to the lung, but severe forms of PTB may also spread into the systemic 
circulation and cause miliary TB that involves the lung as well as other organs.  
 
2.5.2.2 Extrapulmonary TB (EPTB) 
EPTB can occur as a local disease primarily in the lymph nodes or pleura, but EPTB 
can also be presented together with PTB, either in a localized or in a disseminated 
form. EPTB is usually considered a more difficult diagnostic problem than PTB 
because the disease involves relatively inaccessible sites where few bacilli can cause 
great damage. The paucibacillary nature of EPTB in combination with inaccessible 
disease sites, causes bacteriological confirmation of TB to be more difficult and 
invasive procedures are often required to confirm a TB diagnosis [322].  
 
2.5.2.3 Lymph node TB 
It has previously been shown that local TB lymphadenitis accounts for about 10% of all 
TB cases. Although lymph node TB has been considered as a disease of children, the 
peak age for lymph node TB in recent years has been 30-40 years [323]. In addition, 
lymph node TB is more common among women and patients of Asian descent [323]. 
Studies from non-endemic countries have revealed that immigrants from South-east 
Asia, India and Africa appear to have a special predilection to develop TB 
lymphadenitis [324-329]. The basis for the enhanced risk among women, Asians and 
Africans is not known. Possibly, determining host factors involve occupation or 
cultural practices favoring oro-pharyngeal exposures to strains of the Mtb complex (e.g. 
exposure to M. bovis or Mtb from milking cows), genetically determined organ 
tropism, hormonal inﬂuences, effects related to BCG immunization and differences in 
health-seeking behavior [323]. In addition, genetic differences in the virulence of 
different strains of Mtb may play a role [330, 331]. 
TB lymphadenitis usually presents as a slowly progressive, painless swelling of a single 
group of lymph nodes, usually in the cervical region [332, 333]. The duration of 
symptoms at the time of presentation is typically 1-2 months and chest X-ray ﬁndings 
may be positive in 10%–40% of the patients [325, 332, 333]. A deﬁnitive diagnosis of 
TB lymphadenitis can be made by Mtb culture, polymerase chain reaction (PCR) or 
histopathological examination of fine-needle aspirations to demonstrate the presence of 
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Mtb or Mtb-infected cells in the affected lymph node. Excisional biopsy is the most 
invasive approach in diagnosis; however, it has the highest sensitivity and may produce 
a more rapid and favorable symptomatic response [332].  
Mtb is the most common cause of TB lymphadenitis [334]. Accordingly, PCR-based 
studies have shown that Mtb is the main etiological agent of lymph node TB in 
Ethiopia [335, 336]. In some patients with TB lymphadenitis, the response to therapy 
may be slow or paradoxical. Such paradoxical upgrading reaction (PUR) has been 
reported in around 20% of HIV-negative TB lymphadenitis patients [325, 337, 338]. 
One deﬁnition of PUR is the development of enlarged nodes, new nodes or a new 
draining sinus in patients who have received at least 10 days of anti-TB treatment 
[338]. These features are consistent with the initiation of a robust immune response to 
Mtb upon administration of antibiotic therapy, which leads to release of mycobacterial 
antigens [323]. Steroids have been considered as a means to reduce the robust immune 
response in PUR, but their use is controversial; even though some reports describe a 
beneﬁcial effect of steroid treatment [339, 340]. Instead, surgical excision combined 
with standard antibiotic therapy has been shown to produce favorable outcomes [341]. 
 
2.5.2.4 Pleural TB 
The proportion of TB patients with pleural effusions has varied markedly from county 
to country ranging from 20-25% [342, 343]. The pleural effusions secondary to TB 
pleurisy are usually unilateral and can be of any size. Approximately 20% of TB 
patients with pleural effusions have co-existing parenchymal disease detected on chest 
X-rays [344]. The pathogenesis of pleural TB and the formation of pleural effusion is 
thought to be related to the initiation of a delayed hypersensitivity reaction (DTH) and 
the subsequent rupture of a sub-pleural caseous focus in the lung into the pleural space 
[345]. Evidence for the role of hypersensitivity was shown in studies where Mtb protein 
was injected into the pleural spaces of guinea pigs sensitized to puriﬁed protein 
derivative (PPD), whereupon an exudative pleural effusion rapidly develops [346]. 
Most patients with TB pleurisy have more than 50% small lymphocytes in their pleural 
ﬂuid and many have more than 90% [344, 345]. Accordingly, in vivo administration of 
an anti-lymphocyte serum to the sensitized guinea pigs prevented  the development of 
the pleural effusion, which suggests that lymphocytes are important mediators of this 
inflammatory reaction when Mtb components gains access to the pleural space [347]. 
Mycobacterial cultures of pleural ﬂuid samples obtained from pleural TB patients are 
usually negative [348, 349], which further support the notion that Mtb components, 
rather than viable bacteria, promote the development of the pleural effusion.  
The chain of immunological events leading to accumulation of fluid in the pleural 
cavity is assisted by an increased permeability of the pleural capillaries to proteins, 
which results in a much higher rate of pleural ﬂuid formation. In addition, the 
lymphocytic pleuritis obstructs the lymphatic drainage in the parietal pleura, which 
prevents proper clearance of the pleural ﬂuid. Thus, the accumulation of pleural 
effusion is a result of an increased formation of pleural ﬂuid and the decreased removal 
of this fluid [350]. The most common diagnostic method of TB pleurisy is the 
demonstration of TB granulomas in the parietal pleura in tissue biopsies from the 
pleura [344]. TB diagnosis can also be based on elevated levels of adenosine deaminase 
(ADA) or IFN-γ in the pleural ﬂuid [351-354]. Without treatment, TB pleurisy usually 
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resolves spontaneously, but the patient frequently develops active TB at a later time-
point [355]. Similar to PUR in TB lymphadenitis patients, paradoxical worsening of the 
pleural effusion occurs in few patients after the initiation of anti-TB therapy [356].  
 
2.5.2.5 TB/HIV co-infection 
TB/HIV co-infection is one of the main factors that fuel the TB epidemic worldwide 
[357]. The prevalence of HIV infection in patients with TB is highest in the African 
region, which accounts for almost 80% of all TB/HIV co-infected cases worldwide. 
Among all TB patients with an HIV test result, 44% were tested positive in 2011, 
ranging from 8% in Ethiopia to 77% in Swaziland [358]. According to WHO, TB 
remains the leading cause of death among HIV-infected patients and those with latent 
Mtb infection are at high risk of progression to active TB in the absence of preventive 
therapy. A study done on South African gold miners, from 1990 to 2002, showed TB 
as the cause of death in almost 50% of HIV-seropositive patients [359]. Furthermore, 
evidence of TB was found in almost 50% of post-mortem autopsies performed on 
HIV-infected individuals in Kenya including disseminated TB in 80% of the cases 
[360]. Within areas of high TB incidence, the risk of developing active TB is 
significantly increased, even during the first year after HIV transmission, when total 
CD4 T cell counts are still quite high [361, 362]. Thus, the dramatic increase in active 
TB associated with HIV infection suggests that Mtb-specific immunity might be 
particularly vulnerable to HIV-associated immune defects [363]. Mtb-specific CD4+ 
T cells are depleted in peripheral blood early after HIV infection, whereas these do 
not change significantly over a 6-12 month time in HIV-negative subjects with latent 
TB infection [364]. Remaining CD4+ T cells may be functionally inactivated or 
develop immunosuppressive functions. A consequence of the HIV-induced negative 
effects on T cell as well as macrophage responses includes defective granuloma 
formation (Figure 6). Destruction of the TB granuloma ultimately results in extensive 
dissemination of Mtb in TB/HIV co-infected patients. 
 
 
 
 
Figure 6. Defective granuloma formation in TB/HIV co-infected patients. As illustrated, 
deficient TB granuloma formation is dependent on the degree of immunosuppression in HIV-
infected individuals. 
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HIV infection will affect both the immune response as well as the clinical presentation 
of active TB among patients with different forms of disease. In TB/HIV co-infected 
patients with PTB, atypical chest X-ray findings are more common compared to HIV-
negative patients with PTB [322]. Here, the nature of the X-ray findings often depends 
on the degree of HIV-associated immunosuppression. TB that develops relatively early 
in the course of HIV infection tends to present with more typical radiographic findings 
[365, 366], but with more advanced HIV disease, the radiological findings become 
more atypical and cavitation is uncommon [322]. 
Before the beginning of the HIV epidemic, approximately 85% of reported TB cases 
were limited to the lungs and the remaining 15% involved extrapulmonary or both 
pulmonary and extrapulmonary sites [367]. This proportional distribution is 
substantially different among persons with HIV infection. One large retrospective study 
of TB in patients with advanced HIV infection reported that only 38% had PTB while 
30% had a local EPTB and 32% presented both pulmonary and extrapulmonary 
involvement [368]. Thus, EPTB is more common among HIV-infected patients [369, 
370]. The pathogenesis of PUR in HIV-positive TB lymphadenitis patients is complex, 
because HIV patients who started antiretroviral therapy (ART) sometimes develop 
immune reconstitution inflammatory syndrome (IRIS) that also contributes to an 
exaggerated inﬂammatory response [371]. It has also been shown that the proportion of 
thoracic TB patients who developed pleural effusions was higher among HIV-positive 
patients compared to immunocompetent TB patients [343, 372, 373]. The clinical 
manifestations of TB pleurisy also tend to be different in HIV-infected patients with a 
longer duration of illness [374] and thus systemic signs and symptoms are more 
common [375]. Pleural ﬂuid obtained from TB/HIV co-infected patients, is more likely 
to be smear- and culture-positive for mycobacteria [374, 376] and if the peripheral CD4 
T cell count is less than 100 cells/mm3, approximately 50% of patients will show 
detectable AFB in their pleural ﬂuid [374]. Moreover, HIV viral load is usually higher 
in the pleural ﬂuid compared to the peripheral serum, which may indicate active HIV 
replication at the site of TB infection [377]. 
 
2.5.3 TB diagnosis 
2.5.3.1 Commercial methods for TB diagnosis 
TB is unique among the major infectious diseases because of the lack of an accurate 
rapid point-of-care diagnostic test. Failure to control the spread of TB is largely due to 
our inability to detect and treat all infectious cases of PTB, allowing continued 
transmission of Mtb in the society.  Early case detection is dependent on test accuracy, 
accessibility, cost and complexity [42]. A combination of epidemiological, clinical, 
radiological, microbiological and histopathological features is used to verify a diagnosis 
of active TB (Figure 7) [378]. This battery of methods contributes to diagnostic delays 
with serious consequences for public health efforts to control TB disease [379]. In 
Africa only about 60% of the estimated number of TB cases are detected and thus 
close to half of active TB cases remain undetected and continue to transmit 
contagious TB disease [7]. Unrecorded numbers of active TB cases are particularly 
high among TB/HIV co-infected patients. The clinical examination is considered to be 
the first step in TB diagnosis [380]. Imaging techniques like chest X-ray are used to 
detect signs consistent with immune cell infiltrates, dense TB lesions and cavitation. 
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Histopathology can be useful to detect epithelioid granulomas and caseous necrosis that 
are typical findings in tissue or cell samples from patients with EPTB. In addition, 
microbiological techniques including AFB microscopy of sputum samples, Mtb-culture 
of sputum or tissue/body fluid specimens (golden standard) and molecular tests such as 
Mtb-specific PCR are used to detect the presence of  Mtb. Mtb-specific Nucleic Acid 
Amplification tests (NAATs) can be a valid surrogate for direct isolation of Mtb bacilli 
[6]. One of the weak points of the microbiological techniques is that diagnostic 
performance relies on the presence of Mtb bacilli in the analyzed specimen. A test 
capable of diagnosing TB independently of the presence of live Mtb or mycobacterial 
components in the analyzed specimen would significantly improve the diagnosis of 
EPTB and smear-negative PTB cases [381]. 
In contrast to direct identification of Mtb using bacteriological methods, indirect 
methods that measure the immune response to Mtb can be helpful. Immunological 
diagnostic tests such as the Tuberculin Skin Test (TST) and the whole blood based 
Interferon-Gamma Release Assay (IGRA) including T-SPOT TB or QuantiFERON, 
are currently used in health care to assess the immune response against Mtb [382]. 
However, neither TST nor IGRA can separate active TB from latent TB or an old TB 
infection and thus these tests are less useful in high-endemic countries where latent TB 
is common. Furthermore, serological tests showed unsatisfying diagnostic 
performance (low specificity and sensitivity) to detect active TB in randomized 
controlled trials and therefore the clinical use of serology has been questioned by the 
WHO [383].  
 
 
 
 
 
 
 
 
 
 
Figure 7. Pie chart illustrating the principal methods used in TB diagnosis. 
 
2.5.3.2 Poor performance of TB diagnostic methods in certain patient groups 
The only group of TB patients where a definite diagnosis can be both rapid and cheap is 
patients with sputum-smear positive PTB. But sputum-microscopy is used mainly for 
suspected PTB cases and performs poorly in young children [319] and in 
immunosuppressed individuals [379]. Accordingly, the sensitivity of sputum-
microcopy is low, 60% at best and only 30-40% in HIV-infected patients with PTB 
[384]. TB diagnosis also becomes challenging among patients with smear-negative 
PTB or EPTB, due to presentation of diffuse clinical manifestations, low bacterial 
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loads or it is difficult to obtain clinical specimen from the site of Mtb infection, which 
complicates TB diagnosis using commercially available tests. Therefore, diagnosis of 
smear-negative PTB and EPTB is often delayed and sometimes based on the clinical 
response to empiric anti-TB treatment without microbiological confirmation [385, 
386]. Similarly, childhood TB is associated with more problematic diagnosis because 
of atypical clinical manifestations [380, 387], low mycobacterial loads and difficulties 
to obtain sputum samples that are suitable for microbiological analysis [380, 388]. As 
a result, a golden standard for TB diagnosis of childhood TB is still missing [389]. 
Furthermore, upon development of TB in HIV-infected or AIDS patients, TB 
disease is not only more severe at the clinical level, but it also becomes more difficult 
to diagnose TB because of the higher proportion of atypical cases. Because TB/HIV 
co-infected patients often fail to form productive granulomas [390], bacteria less 
frequently enter the airway system and thus the proportion of sputum-negative TB 
cases paradoxically increases.  
 
2.5.3.3 Challenges in TB diagnosis 
The diagnostic challenges described above are most problematic in TB endemic 
countries. It is therefore important that a diagnostic technique intended for TB control 
at a global level should be suitable for use in a setting where it is most needed, 
namely in resource-poor high-burden countries in Africa and Asia [42]. In 
industrialized countries, radiology advanced imaging techniques, rapid and automated 
systems for mycobacterial growth (ie. BACTEC Mycobacterial Detection System),  
and NAATs are used to supplement light and light-emitting diode (LED) microscopy 
for the diagnosis of active TB disease [6]. Unfortunately, many of these technologies 
are too advanced and too expensive to be used in routine diagnosis in the developing 
world. In resource-limited settings, microscopic examination of Ziehl-Neelsen stained 
sputum specimens is often the only TB test available. The ideal TB test would  
provide an on-the-spot accurate diagnosis of : 1) active TB in both HIV-negative and 
HIV-positive TB patients, 2) active TB in both adults and children, 3)  both PTB and 
EPTB, 4) both sputum-positive and sputum-negative patients [391]. The ability of an 
efficient diagnostic test to distinguish between active TB disease and latent TB 
infection is also critical [42]. 
 
2.5.3.4 Recent advances in TB diagnosis 
IGRA: UK National Institute for Health and Clinical Excellence guidelines 
recommends the use of the IGRA tests combined with traditional TST and other routine 
TB diagnostic tests in the screening of patients with suspected TB. IGRAs that are 
based on the detection of Mtb-specific T cells, are an improvement over the TST since 
these assays produce less false positives caused by mycobacteria other than 
tuberculosis (MOTT) or BCG vaccination, have an internal control and do not require a 
follow-up visit to assess the reaction. 
 
GeneXpert: The Xpert MTB/RIF assay is a major advance among a new generation of 
automated easy-to-use nucleic acid amplification tests. This PCR-based assay is a very 
sensitive diagnostic test for detection of Mtb bacilli in sputum and other clinical 
samples and is also useful to detect rifampicin resistance in high-risk populations as 
well as  low-risk populations [392-394]. Despite the high sensitivity and specificity of 
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the GeneXpert among sputum-positive patients with PTB, the performance of this test 
in sputum-negative high risk groups is still sub-optimal. Therefore GeneXpert cannot 
be universally applied as a definitive test for point-of-care.  
 
Urine-based diagnostic tests: Commercial assays are available that can detect LAM in 
the urine of patients with active TB, ie. the Determine TB-LAM is a commercially 
available, lateral-flow urine ‘strip test’ assay [395]. Although the sensitivity of this test 
has been disappointing in HIV-negative TB patients, moderate sensitivity and high 
specificity has been observed in HIV-infected TB patients with advanced 
immunodeficiency [396].  
 
Serological tests: Commercial serological tests for detection of active TB have been a 
disappointment so far, showing overall low quality including inconsistent and 
imprecise estimates of sensitivity and specificity. Furthermore, there is no evidence that 
existing serological assays improve patient-important outcomes. Studies have found 
considerable variation in Mtb-specific antibody responses detected in TB patients, 
suggesting that multiple targets will be needed if antibody-based tests are to achieve the 
required sensitivity [397, 398].  
 
Flow cytometric assays: In a study performed on Mtb-specific T cell responses using 
flow cytometry, the proportion of TNF-α single-positive Mtb-specific CD4+ T cells 
were found to be the strongest predictor of active TB disease. The sensitivity of the 
CD4+ T cell signature was 100% and the specificity was 96% for these data that were 
generated from a European cohort [399]. 
 
2.5.4 Treatment of TB 
2.5.4.1 TB chemotherapy 
Drug treatment is the corner stone of TB control and a clinical cure if followed 
properly. A review of the pre-chemotherapy era showed that HIV-negative patients 
with an untreated smear-positive TB has a 10-year case fatality of 53-86% (weighted 
mean of 70%) [400]. The duration of TB from onset of disease to cure or death is 
approximately 3 years and appears to be similar for smear-positive and smear-negative 
cases [400]. Before effective antibacterial treatment was developed, the historical 
medical therapy for TB was based on isolation of the TB patient in a sanatorium where 
the patients could rest in fresh cold air [401]. Some of the TB patients were indeed 
cured at the sanatorium. It has been speculated that their clinical recovery was 
enhanced after exposure to sun light, which is known to promote the production of 
vitamin D in the skin that can enhance anti-mycobacterial effector functions in human 
macrophages [402]. The first TB patient was treated with streptomycin in 1944 and she 
was cured from her life-threatening disease! Further trials confirmed that streptomycin 
was indeed effective in the treatment of TB. Selman Waksman was awarded the Nobel 
Prize in Physiology or Medicine in 1952 for his discovery of streptomycin (Nobel 
prize.org, tuberculosis). Nowadays, standard drug regimen for effective treatment of 
chronic TB involves a combination therapy with first- and/or second-line drugs for 6-8 
months. Recommended first-line anti-TB drugs includes rifampicin, isoniazid, 
pyrazinamide and ethambutol for 2 months, followed by rifampicin and isoniazid for 4 
months [403]. 
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2.5.4.2 Drug resistant TB 
The extended multidrug therapy that is typically used to treat patients with active TB 
prevents the emergence of drug resistance, but also contributes to a low compliance 
among the TB patients. Importantly, many patients feel better already a couple of 
weeks after initiation of anti-TB chemotherapy and therefore stop taking their drugs, 
which also has many unwanted side-effects. This opens up an opportunity for residual 
bacteria remaining in the infected organ to start to replicate and grow out a drug-
resistant population of Mtb that will be much more difficult to treat. Recently, 
increasing numbers of MDR-TB, and also extensively drug-resistant (XDR) TB and 
totally drug-resistant cases threaten TB control all over the world [404, 405]. 
 
2.5.5 TB vaccine 
2.5.5.1 BCG vaccine 
BCG is the first TB vaccine and is still being used as the only TB vaccine in routine 
clinical practice. In 1908, Albert Calmette and Camille Guerin at the Institute of 
Pasteur, made the attenuated form of M. bovis from a virulent M. bovis strain which 
was then used for the development of the first TB vaccine [406, 407]. BCG is the most 
extensively used vaccine with more than 4 billion doses administered worldwide [408]. 
BCG is a most debated vaccine as it provides varying protection against TB which 
varies extensively comparing different populations and geographic locations in the 
world [409, 410]. Although BCG confers protection against severe forms of TB in 
children such as meningitis and disseminated TB, the estimated protection ranges from 
0-80% in adult PTB [3]. Several factors are likely to influence the inconsistency in 
BCG-induced protection. Some of these are batch differences in the many strains of 
BCG in use, which differ in immunogenicity [411]. Moreover, BCG differs from Mtb 
in that it lacks the RD1 region that encodes for many of the specific virulence proteins 
expressed by Mtb. The absence of RD1 in BCG will probably result in a failure of BCG 
to induce Mtb-specific T cell responses [412, 413]. 
 
2.5.5.2 Improvement of the BCG vaccine 
The development of efficient memory CD4+ and CD8+ T cell responses is the main 
requirement of a novel vaccine against Mtb [194]. In an attempt to improve BCG 
vaccination, it could be possible to boost the initial BCG response by delivery of the 
RD1-specific antigen(s) (i.e. ESAT-6 or CFP10) together with an adjuvant. Boosting 
BCG-primed mice with a recombinant adenovirus expressing Mtb antigen (Ag)85A by 
the intra-nasal route was associated with the induction of immune protection that 
correlates with the presence of polyfunctional T cells expressing high levels of Th1 
cytokines (IFN-γ, IL-2 and TNF-α) [414]. Boosting of BCG-induced responses in 
humans also results in expansion of long-lived polyfunctional T cells expressing IFNγ, 
IL-2 and TNF-α [415]. Current knowledge of the immune response to Mtb has not 
allowed for a dramatic improvement in the design of vaccines, even though many new 
vaccine constructs are currently being tested in clinical trials. Once TB disease has 
developed, a delicate balance between protective and pathological immune responses is 
the key to survival. Thus, T cell functional data has to be integrated with an analysis of 
the consequences of TB infection itself to improve rational vaccine design [192]. 
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2.6 THE FUTURE: NEW DRUGS AND BIOMARKES FOR TB 
It is generally accepted that reasonable control of TB on a global scale depends on new 
interventions including a better vaccine that protects adults against PTB, better drugs 
that act on dormant Mtb and shorten treatment of active TB as well as better diagnostic 
tests with the ability to rapidly detect active TB. Due to the extended duration of anti-
TB drug treatment that spans over months, the benefits of potential resolution 
mediators, that could lower antibiotic requirements, merit attention [43]. Here, a study 
also showed a potential role of adjunctive treatment with vitamin D to standard 
treatment of PTB that could accelerate resolution of inflammatory responses 
associated with increased risk of mortality [416]. After many years, a new anti-TB 
drug has been approved in the US for restricted use and this drug is in the late phases of 
clinical development and is being tested in patients with MDR-TB. This is bedaquiline, 
a diarylchinolone, which blocks the ATP synthase in the bacteria and probably also acts 
on dormant Mtb [417, 418]. Currently, a dozen preventive TB vaccine candidates and a 
few therapeutic ones are undergoing clinical trial assessment [418].  
Moreover, studies of novel biomarkers, comparing gene expression profiles in patients 
with active TB with latently infected healthy individuals, have provided proof of 
principle for the discovery of bio-signatures that reliably discriminate active from latent 
TB [43]. Besides the primary goal of identifying new diagnostic tools, biomarkers also 
provide deep insights into biological mechanisms operative in TB disease and latent TB 
infection [43]. A whole-blood microarray gene expression analyses performed in TB 
patients, showed that FcγR was one of the most discriminative markers giving a high 
degree of accuracy in discriminating TB patients and latently infected donors [419]. Fc 
receptors bind to antibodies and stimulate phagocytic or cytolytic cells to destroy 
microbes, by phagocytosis or cytotoxicity. On the contrary some viruses use Fc 
receptors to infect cells by ADE [420]. FcγR are the most important Fc receptors for 
inducing phagocytosis of opsonized microbes, on the other hand they can also be 
released in cell supernatant and circulate in biological fluid and bind to 
immunoglobulin’s, interfering with their function [421]. A study performed in a cohort 
from Gambia, showed that the gene expression of FcγR1 was one of the most 
differentially expressed genes in active TB compared to latent TB [422]. Similar 
results were provided in cohorts from both Europe and South Africa [419, 423]. 
Elevated levels of immune complexes accompanied by defective immune complex 
solubilization have also been documented in serum of TB patients as potential 
attractive biomarkers of active TB [424].  
In the context of intracellular microbes such as Mtb and also HIV, for which effective 
vaccines are lacking, an increased understanding of how B cells regulate the immune 
response to pathogens and how antibody-dependent immunity interacts with the 
cellular arm of the host response to mediate protective effects will likely aid in the 
development of strategies to enhance antimicrobial immunity and vaccine efﬁcacy 
[425]. The large plasticity of the human immune system including an integrative 
understanding of how immune cells cooperate to control infection is essential to 
improve vaccine design and immune response monitoring, because no single cell or 
effector function can be solely related to immune protection in TB [146]. The search 
for specific signature molecules of active TB disease continues to be essential. 
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3 AIMS, RESEARCH DESIGN AND METHODS 
In this chapter, an overview of the aims, experimental design and methods used in this 
thesis work will be explained. Details regarding individual experiments can be found in 
the Materials and Methods sections in each of the papers included in this thesis.  
 
3.1 AIMS 
This thesis focused to explore immune responses in human TB in order to increase the 
understanding of the immunopathogenic mechanisms associated with progression of 
active TB disease in HIV-negative and HIV-positive individuals. The aim was to use 
this new knowledge to identify relevant biomarkers or immune response signatures 
specific for clinical TB. 
 
 Study I:  To dissect the antimicrobial effector pathways and immunoregulatory 
mechanisms at the site of infection in children with a local lymph node TB. 
 Study II: To evaluate a new diagnostic plasma B cell test for detection of active 
TB in adult patients with different clinical forms of TB.  
 Study III: To explore the expression and regulation of cytokine/chemokine 
profile in adult patients with pulmonary and pleural TB.  
 Study IV (ongoing): To study the effects of HIV infection on tissue 
inflammation and remodeling in adult patients with a local lymph node TB. 
 
3.2 PATIENTS AND CLINICAL SAMPLES 
3.2.1 Study site 
All study subjects were recruited at the Black Lion University Hospital located in 
Addis Ababa, Ethiopia (Figure 8). The children were recruited from the Department of 
Pediatrics (Study I), while adult patients were recruited from the Department of 
Internal Medicine (Chest unit) at the hospital (Study II-IV). The Black Lion Hospital is 
the largest, general specialized and referral teaching hospital in Ethiopia that cares for 
many TB-infected and TB/HIV co-infected patients every year. A control group of 
children with tonsil hyperplasia (Study I) as well as healthy blood donors (Study III) 
were also recruited at the Karolinska University Hospital in Huddinge, Sweden. The 
laboratory analyses were performed at the Armauer Hansen Research Institute (AHRI) 
in Addis Ababa, Ethiopia (Figure 8) and also at the Center for Infectious Medicine 
(CIM), Karolinska Institutet, Sweden. 
 
 
Figure 8. The Black Lion University Hospital (left) and the Armauer Hansen Research Institute 
(right) in Addis Ababa, Ethiopia. 
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3.2.2 Study cohorts 
This thesis study was designed to explore immune responses in patients with a sputum-
negative active TB as compared to appropriate control groups: 
 Study I: Ethiopian children with a local persistent TB lymphadenitis, age 3-10 
years (n=11).  
Controls: Age-matched children:  
o Ethiopian children with a non-specific reactive lymphadenitis (n=10). 
o Swedish children with a non-infectious tonsil hyperplasia (n=10). 
HIV status: All study subjects were HIV-negative. 
 Study II: Ethiopian adult patients >18 years with different clinical forms of 
TB: 
o Pulmonary TB (n=35) 
o Pleural TB (n=23) 
o Lymph node TB (n=26) 
Controls: Ethiopian adult patients >18 years: 
o Asymptomatic individuals with latent TB (n=45) 
o Asymptomatic individuals with neither latent or active TB (n=40) 
o Symptomatic patients with other diseases than TB (n=12) 
HIV status: The study subjects included both HIV-negative and HIV-positive 
individuals.  
 Study III: Ethiopian adult patients >18 years with different clinical forms of 
TB: 
o Pulmonary TB (n=35) 
o Pleural TB (n=23) 
Controls: Adult patients >18 years: 
o Individuals with a bronchial wall irritation (noninflammatory) (n=10) 
o Patients with pleural diseases other than TB (n=5)  
HIV status: The study subjects included both HIV-negative and HIV-positive 
individuals.  
 Study IV (ongoing): Ethiopian adult patients >18 years with a local persistent 
TB lymphadenitis (n=18).  
Controls: Ethiopian adult patients >18 years with a non-specific reactive 
lymphadenitis (n=10). 
HIV status: The study subjects included both HIV-negative and HIV-positive 
individuals.  
These are well-defined study cohorts where all subjects had a clinical (typical clinical 
symptoms including persistent cough, fever, sweating and weight loss), radiological 
(chest X-ray abnormality consistent with TB) and laboratory diagnosis (culture of 
bronchoalveolar lavage (BAL), histopathological examination of cells or tissue biopsies 
and/or Mtb-specific PCR) of active TB. At the time of inclusion, all patients were 
treatment naïve for both TB (standard anti-TB chemotherapy) and HIV drugs 
(antiretroviral therapy). Patients with a diagnosis of TB were treated with anti-TB drugs 
and followed for 8 months. In cases of clinical TB (patients without bacteriological 
confirmation of Mtb), the response to anti-TB treatment (radiological resolution of 
pulmonary or pleural lesions and clinical improvement) was used as a retrospective 
diagnostic criteria for TB. 
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3.2.3 Clinical samples 
At the time of TB diagnosis, clinical samples were obtained both from the site of 
infection (pleura or lymph node tissue, BAL or pleural fluid) and from the peripheral 
circulation (blood) (Figure 9). All tissue biopsies were cryopreserved in liquid nitrogen 
and stored in -85°C until laboratory analysis. Cells isolated from BAL and pleura fluid 
and peripheral blood mononuclear cells (PBMCs) isolated from blood samples were 
stored at -150°C. BAL and pleura fluid supernatant and plasma obtained from blood 
were stored at -85°C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Schematic illustration of the clinical samples collected from the study subjects. 
LNTB=lymph node TB and PTB=pulmonary TB. 
 
3.3 EXPERIMENTAL METHODS 
This thesis is based on comprehensive analysis of clinical samples obtained from TB 
patients and controls. In summary the following techniques were used to study immune 
responses in human TB: 
 
 Immunohistochemistry and in situ computerized image analysis: Study I and IV  
 Multiplex Luminex Assay: Study III 
 Enzyme Linked Immunosorbent Assay (ELISA): Study II and III 
 Flow cytometry: Study II 
 Quantitative real-time PCR (qPCR): Study I, III, IV 
 Immunodiagnosis of TB (ALS, TST and QFTG): Study II  
 
All work with Mtb-infected cell and tissue samples have been performed at biosafety 
level 3 (BSL-3) laboratories at AHRI in Ethiopia and at the Swedish Institute for 
Communicable Diseases Control (SMI) in Sweden. After chemical inactivation of Mtb 
or filtration of body fluids, the samples could be transferred to BSL-2 laboratory for 
continued analysis. A theoretical description of the key methodologies is provided 
below. 
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3.3.1 Immunohistochemistry (IHC) 
Immunohistochemistry (IHC) is a method used to detect protein expression and 
distribution in tissue using phenotypic and functional markers. IHC and in situ 
computerized image analysis is a well-established technology in our laboratory and has 
been used to study immune responses in TB, HIV and Streptococcus infection [426-
429]. In Study I and ongoing Study IV, IHC provided us with a unique advantage to 
study the spatio-temporal organization of cells and effector molecules in the intact 
tissue. Thus, tissue inflammation and architecture including granuloma formation could 
be studied in a physiologically relevant milieu at the site of Mtb infection.  
 
3.3.1.1 Cryosectioning of Mtb-infected tissue samples 
Lymph node biopsies from TB patients were cryopreserved in order to prevent 
destruction and loss of sensitive epitopes. Since Mtb is resistant to cold, freezing and 
desiccation [430], work with frozen biopsies from Mtb-infected patients is not without 
risk. To be able to perform this work, our group has established a facility suitable for 
cryosectioning of Mtb-infected tissues in the BSL-3 laboratory at SMI. In this facility, a 
cryostat is covered by a custom-made ventilation hood that prevents potential spread of 
infectious aerosols. This special construction allows safe and efficient processing of 
Mtb-infected frozen tissue samples. Ultrathin sections of 8 microns each are cut from 
the tissue biopsies and mounted on microscope slides before fixation and inactivation in 
4% formaldehyde. 
 
3.3.1.2 In situ computerized image analysis 
Antimicrobial and immunoregulatory pathways in TB were investigated using IHC and 
in situ computerized image analysis, which provides an excellent technological 
platform to explore local immune responses in clinical tissue samples. The Avidin-
Biotin Complex (ABC) method was used for IHC detection. IHC is a semi-quantitative 
method to study protein expression in cryopreserved tissue. Immunostainings enable 
visualization of tissue morphology, expression and distribution of cells and effector 
molecules, specific cell-cell interactions as well as the anatomical location of 
mycobacteria or mycobacterial antigens. Thus, IHC enables functional assessment of 
various proteins at the single-cell level, including cell surface, cytoplasmic and nuclear 
as well as granule-associated and secreted proteins in the complex environment of real 
tissue. High-resolution images can be taken at different magnifications using a digital 
camera that is connected to the microscope (Leica Microsystems). Furthermore, protein 
expression can be quantified at the single-cell level using a highly sensitive 
computerized image analysis program (Leica Qwin). The Leica Qwin software can 
differentiate an extensive range of colors (up to 16.7 million) and thus support detailed 
assessment of different proteins in the tissue. It is also possible to choose different 
applications of the software, such as tissue-excluder or tissue-includer analysis. These 
functions can be used to exclusively analyze certain areas of the tissue, such as a TB 
granuloma. Co-expression of surface-expressed and/or intracellular proteins can also be 
detected using multicolor labeling (immunofluorescence) and confocal microscopy that 
can be manually quantified. In summary, this method can be widely used to study the 
expression of many different proteins in human tissues. 
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3.3.2 Multiplex luminex assay 
The multiplex luminex is a microplate bead-based protein detection immunoassay that 
was used to examine the cytokine and chemokine profiles in active TB patients and 
controls (Study III). The aim of this analysis was also to compare the 
cytokine/chemokine profile at the site of Mtb infection (BAL or pleural fluid) to 
peripheral blood (plasma). The advantage with the multiplex luminex assay is that it 
detects several cytokines and chemokines in the same clinical samples, which provides 
the opportunity to map the relative expression levels of many proteins simultaneously.  
 
3.3.2.1 Protein assessment using multiplex luminex 
The multiplex luminex system enables to detect up to 100 different analytes in a small 
test sample, allowing sensitive quantification of many different cytokines and 
chemokines in the same sample. Microscopic beads with different color codes (spectral 
addresses) permit discrimination of individual assays. In addition, the beads are 
internally dyed with different ratios of fluorophores and are thus classified into unique 
bead regions. Beads with different spectral addresses are selected and coupled to 
antibodies against a different target. These antibody-coupled beads are added to a 96-
well plate before addition of the test sample. The targets, cytokines and chemokines, in 
the sample are detected by biotin-labeled detection antibodies specific for secondary 
epitopes on each target. A fluorescent-labeled streptavidin reporter is used to bind to 
the biotin-labeled antibodies, where after the reaction is read on a Bio-plex reader. 
Dyed beads are identified by their bead region and the level of target is indicated by 
intensity of the reporter signal. All multiplex data are reported simultaneously and 
analyzed by the Bio-plex manager 4.0 curve fitting software using the five parametric 
algorithms. 
 
3.3.3 Enzyme-linked immunosorbent assay (ELISA) 
A standard ELISA was performed to assess BCG-specific IgG antibodies produced in 
lymphocyte supernatants (Study II) and also in plasma, BAL and pleural fluid (Study 
III) from TB patients and controls. A Japan BCG vaccine was used as coating antigen 
and after incubation with the clinical samples, the ELISA was developed using a rabbit 
anti-human IgG horseradish peroxidase (HRP) conjugate and an O-phenylenediamine 
(OPD) substrate. 
 
3.3.4 Flow cytometry (FACS) 
In Study II, multicolor flow cytometry (FACS) was applied to detect and quantify the 
presence of IgG-expressing plasmablast in the peripheral circulation of TB patients and 
controls. FACS is a laser-based technique used for cell counting and sorting, which 
allows simultaneous detection and analysis of multiple markers expressed on the same 
cell and can be used to detect rare subsets of cells. Here, FACS analysis of PBMC 
samples included a panel of plasmablast markers (CD3, CD20, CD27, CD38, CD19  
and IgG) that were evaluated using a Gallios flow cytometer and the Kaluza software. 
Plasmablasts were identified as CD3-CD19+CD20-CD27highCD38high cells that 
expressed membrane-bound IgG. 
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3.3.5 Quantitative real-time PCR (qPCR) 
A convenient method has been developed in our research group to quantify mRNA 
expression of different host molecules in cells and tissues using quantitative real-time 
PCR (qPCR). qPCR analysis is a sensitive method that provides the possibility to study 
the relative expression of transcripts in rare clinical samples. In Study I, III and IV, 
qPCR was used to measure different effector and inhibitory molecules at the mRNA 
level in human TB. mRNA was extracted from human cells (PBMCs, BAL and pleural 
cells preserved in RNAlater) using a phenol-based compound (TRI Reagent), which 
also inactivates any mycobacteria present in the sample. A very small amount of 
clinical material is required to perform the qPCR and once the mRNA has been 
converted to cDNA, the sample could be stored at -20°C for long periods of time.  
 
3.3.6 Immunodiagnosis of TB 
3.3.6.1 Antibodies in Lymphocyte Supernatant (ALS) 
The Antibodies in Lymphocyte Supernatants (ALS) assay is an ELISA-based method 
that detects BCG-specific IgG antibodies secreted by PBMCs cultured in vitro (Figure 
10). In Study II, we used the ALS assay as novel diagnostic method to improve 
detection of active TB among TB patients and controls. The ALS is a novel test that has 
previously been developed by our collaborator Dr. Rubhana Raqib at the International 
Centre for Diarrhoeal Disease Research (icddr,b), Bangladesh [431, 432]. The 
theoretical basis for this assay is that in a steady-state, migratory plasmablasts among 
PBMCs are very low, but significantly elevated upon continuous antigen exposure ie. 
during active TB infection [433, 434]. In the ALS assay (48-well format), PBMCs are 
isolated from peripheral blood and cultured (2x2,5 million cells) for 72 h in the absence 
of exogenous stimulation. The spontaneous release of antibodies from in vivo activated 
plasmablasts results in an accumulation of Mtb-specific IgG in culture supernatants that 
are measured using ELISA and the BCG vaccine as antigen. Thus, the ALS assay is an 
in vitro assay to detect in vivo activated IgG-secreting plasmablasts. Pooled sera from 
sputum-smear positive TB patients are used as positive control while cell culture 
medium is used as negative control. The potential use of the ALS assay as a diagnostic 
test was evaluated in comparison to clinical diagnosis as well as immunodiagnosis 
using the commercially available TST and QFTG test.   
 
3.3.6.2 QuantiFERON (QFTG) 
The QuantiFERON or Quantiferon-TB Gold In-Tube (QFTG) is an ELISA-based test 
to assess Mtb-specific IFN-γ production in whole blood samples from TB patients and 
controls (Study II) (Figure 10). In the QFTG assay, whole blood aliquots are collected 
in tubes pre-coated with a cocktail of three Mtb-antigens, ESAT-6, CFP-10 and TB7.7. 
Importantly, these antigens are absent from BCG and MOTT. IFN-γ production in the 
Mtb-stimulated blood sample is compared to a positive (mitogen) as well as a negative 
control (nil) after incubation for 16-24 hours at 37°C. Individuals that have been 
exposed to Mtb will have memory T cells in their circulation that will respond to the 
Mtb-antigen cocktail by producing IFN-γ. An individual is considered TB-positive if 
the QFTG result is above the test cut-off (>0.35 IU/ml), after subtracting background 
production of IFN-γ in the negative control. Even though the QFTG test does not 
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distinguish active TB from latent TB, the sensitivity of this test is high. In addition, 
since this is a standardized commercial assay, the reader bias is very small, which 
makes QFTG a superior method as compared to TST.  
 
3.3.6.3 Tuberculin Skin Test (TST) 
The Tuberculin Skin Test (TST) is a diagnostic assay for TB that has been routinely 
used for the last century. The TST is based on the presence of a delayed-type 
hypersensitivity reaction in the skin after intradermal injection of 0.1ml (5TU) of 
Tuberculin Purified Protein Derivative (PPD) (Figure 10). The induration of the skin 
reaction (swelling caused by local inflammation) is read after 48-72 hours. The TST is 
considered positive when the transverse diameter of the reaction is ≥10mm in HIV-
negative and ≥5mm in HIV-positive individuals. This test has the capacity to reveal 
exposure to mycobacteria, but it cannot differentiate Mtb infection from MOTT or 
previous BCG vaccination [435]. Despite this obvious drawback, the TST is still one of 
the most common diagnostic tests used in routine clinical practice to detect active TB.  
 
 
 
 
 
 
 
 
Figure 10. Schematic illustration of the immunodiagnostic assays used in this thesis work. 
 
3.4 STATISTICAL ANALYSES 
Non-parametric analyses were used to calculate the p-values for groups of a small 
sample size (n<10) or for non-normally distributed data (D’Agostino and Pearson 
omnibus normality test) and included the Kruskal-Wallis test and Dunn’s post-test 
(comparing more than two unmatched groups), the Mann-Whitney U test (comparing 
two unmatched groups) or the Wilcoxon signed-rank test (comparing two matched 
groups). A p-value <0.05 was considered significant (*), a p-value <0.01 was 
considered very significant (**), a p-value <0.001 was considered extremely significant 
(***), whereas a p-value >0.05 was considered not significant (ns). Spearman’s 
correlation test was used for the correlation analysis. A value of r=1, indicates a perfect 
positive correlation whereas r=-1 indicates a perfect negative correlation. Receiver 
operating characteristics curves (ROC) were used to determine the relation between 
sensitivity and specificity at various cut-off levels of BCG-specific IgG titers and to 
determine the cut-off point based on the level of maximum accuracy. Statistical 
analyses were performed in Graph Pad Prism (Study I, II, III and IV) and SPSS V.12 
(Study II). 
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3.5 ETHICAL CONSIDERATIONS 
Lymph nodes from Ethiopian patients and tonsils from Swedish uninfected controls 
were obtained after ethical approval from both Sweden (EPN dnr: 365/00 and 
2007/141-32) and Ethiopia (Study I). Patients were recruited into the study after 
parent’s or guardian’s approval and signed informed consent. Clinical samples from 
Ethiopian adult patients and controls were obtained after ethical approval from Sweden 
(EPN dnr: 2007/675-31/4, 2011/1014-31/1 and 2010/603-31/4) and Ethiopia (Study II-
IV). Patients and controls were recruited into the study after obtaining signed informed 
consent. 
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4 RESULTS AND DISCUSSION  
In this chapter, the clinical and demographic characteristics of the study population will 
be presented, the experimental results of the thesis will be analyzed and their 
implications discussed. 
 
4.1 CLINICAL AND DEMOGRAPHIC DATA OF THE STUDY COHORT 
4.1.1 Primarily young individuals are infected with active TB 
The demography of the study subjects included in this thesis work is outline in Table 1. 
The mean age of the adult study cohort was 31 years for all forms of clinical TB 
disease (Study II-IV). This is similar compared to a study in South Africa where the 
highest TB notification rates were found in the age group of 30-49 years, which 
typically indicates a shift in the disease burden to individuals in the economically 
productive age groups [436]. Another study on lymph node TB in USA also detected a 
peak in TB disease in the age group of 30-40 years [323]. Interestingly, we observed a 
higher mean age of TB patients who were HIV-positive (36 years) compared to HIV-
negative (29 years) TB patients. This age difference was also observed in HIV-positive 
(33 years) compared to HIV-negative (28 years) control subjects, which indicates that 
this deviation may be related to HIV rather than TB infection. This finding is in 
agreement with a study in Burundi where the mean age of HIV-positive patients with 
intra-thoracic TB (35,8 years) was higher compared to  HIV-negative TB subjects (29,4 
years) [342]. Another study also showed that HIV-positive individuals with (33,4 
years) or without active TB (34,1 years) were generally older than HIV-negative 
controls (25,7 years) [437].  
Similar numbers of males and female were included in the adult study cohort (Study 
II-IV), while there were more females included in the children cohort (Study I) (Table 
1). Our finding in children is consistent with reports showing that TB lymphadenitis is 
seen more frequently in females compared to males in both children and adults [323, 
438].  
 
4.1.2 TB/HIV co-infection is common in the adult study cohort 
HIV-infected individuals and other patient groups with impaired cell-mediated 
immunity are much more likely to develop active TB disease, both from a new 
infection and from reactivation of latent TB. In this study cohort (Study II-IV), 
TB/HIV co-infection was observed in 32% of the adult TB patients (Table 1), which is 
in agreement with a global TB/HIV co-infection prevalence of 39% [1]. Likewise, an 
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Ethiopian study previously showed that 30% of urban patients with TB were HIV-
positive [439]. In contrast, TB/HIV co-infection was very low in our Ethiopian child 
cohort (Table 1) (Study I). Out of a total of 49 children with a suspected TB 
lymphadenitis, only two HIV-positive children with a local TB lymphadenitis were 
found (unpublished observation). Thus, this finding may be explained by the fact that 
we selected children with a local lymph node TB without pulmonary involvement or 
signs of systemic disease. Children are known to be particularly vulnerable to severe 
disease following TB infection, partly because the immune system is not fully mature 
in children [440]. Therefore, TB/HIV co-infection may be more frequently associated 
with systemic disease in children compared to adults [322].  
The clinical data on the adult study cohort also showed that parasite infections were 
rare (11%) and mostly associated to TB/HIV co-infection (Study II), which is 
consistent with the notion that immunosuppressed individuals are more susceptible to 
opportunistic intestinal infections [441]. This finding is also in agreement with a 
previous study from Ethiopia showing that parasitic infections are more common in 
HIV patients [442]. 
 
4.1.3 Low level of BCG vaccination among adult TB patients 
Even though BCG vaccination is known to induce a very variable protection against TB 
in different populations and in different age groups, BCG efficiently protects children 
from severe childhood TB. Since the children were recruited from a pediatric unit 
where children are routinely BCG vaccinated, all children with lymph node TB were 
BCG vaccinated (Study I). Instead, BCG vaccination (detected by a BCG scar) was 
only observed in 20% of our adult TB cohort (Study II-IV). A lower level of BCG 
vaccination among adult TB patients compared to the children cohort could be 
explained by a very low BCG immunization coverage in Ethiopia before 1980, which 
has increased to 72% after 2006 (BCG World Atlas). 
 
4.2 NOVEL IMMUNODIAGNOSTIC ASSAYS OF ACTIVE TB 
4.2.1 Challenges of conventional methods for TB diagnosis 
As described in the Background section of this thesis, diagnosis of TB is difficult and 
rapid bacteriological confirmation of Mtb is only possible in 30-60% of all TB patients. 
High-risk groups that are particularly difficult to diagnose include sputum smear-
negative PTB, TB/HIV co-infection, extrapulmonary forms of TB as well as TB in 
small children. In this thesis work, we decided to include adult sputum-smear negative 
TB cases including both PTB and EPTB cases with and without a concomitant HIV 
infection. Consequently, all of the adult TB patients included in this thesis work were 
sputum-smear negative and comprised 42% PTB cases and 58% EPTB cases (Study 
II-IV). Bacteriological confirmation using BAL samples collected with bronchoscopy 
have been shown to improve the diagnosis of patients with a sputum-negative TB 
[443]. In this study cohort, 69% of the BAL samples obtained from PTB patients were 
culture positive for Mtb (Study II-III), which is consistent with a study observing 75% 
of BAL-culture conﬁrmed TB cases among sputum-negative TB patients [444]. 
Accordingly, the proportion of BAL-culture negative PTB patients in this study was 
31% (Study II-III). These patients were diagnosed based on clinical symptoms, 
abnormal chest X-ray findings and clinical improvement and X-ray resolution of lesion 
   43 
after treatment with anti-TB drugs (Study II-III) [445]. Importantly, bronchoscopy is 
an invasive procedure and not suitable for routine diagnosis in resource-poor settings. 
Instead, better diagnostic assays are urgently required to improve TB diagnosis among 
patients with sputum- and/or BAL-negative TB as well as clinical TB.  
 
4.2.2 B cell-based immunodiagnosis 
4.2.2.1 The ALS assay can improve TB diagnosis in selected high-risk groups 
In Study II, we aimed to investigate if Mtb-specific plasmablast responses, assessed 
with the novel ALS assay, could be used to detect active TB among sputum smear 
negative TB cases and differentiate different forms of active TB (PTB and EPTB) from 
latent TB and healthy controls. The aim was also to study the diagnostic performance 
of the ALS assay among TB/HIV co-infected patients. For the first time, we were able 
to demonstrate that the ALS assay can be used to improve diagnosis of active TB in 
these high-risk groups (Study II). The majority of patients with active TB had a 
positive result with the ALS assay (91%), but also with the TST (89%) and QFTG 
(79%) tests (Study II). The ALS assay has previously been shown to discriminate 
active TB from TB-exposed contacts and also subclinical TB disease [431, 432, 446]. 
Here, we compared the ALS response of active TB patients to a well-defined cohort of 
latent TB controls as well as a control group without either latent or active TB. 
Importantly, the ALS was the only assay that could differentiate active TB from latent 
TB, while neither TST nor QFTG could discriminate active from latent TB (Study II). 
This result suggests that the ALS may be useful to diagnose active TB disease, 
especially in TB endemic areas where latent TB is very common. Some latent TB cases 
(16%) presented a positive ALS response that could be indicative of subclinical TB 
[432], which is associated with an increased risk of developing active TB infection. 
Previous studies of the ALS assay performed by our colleagues in Dhaka, Bangladesh, 
have demonstrated efficient diagnostic capacity of ALS in patients with sputum-
positive TB [431] and also in children [447]. Interestingly, Mtb-specific plasmablast 
responses decrease after 2-6 months of successful standard chemotherapy [432], while 
patients with incurable MDR-TB maintain high IgG titers [448]. Thus, the ALS assay 
may also be used to monitor the response to anti-TB treatment in order to predict the 
development of MDR-TB early on.  
It has been shown that BCG is the superior antigen to detect Mtb-specific plasmablasts 
responses compared to PPD, LAM or selected RD1-encoded antigens [449]. However, 
work is in progress to try and improve the format of the ALS assay including selection 
of a new antigen that could further enhance the specificity of the ALS assay. 
 
4.2.2.2 The ALS assay is particularly useful to detect TB in HIV-infected cases 
It is difficult to diagnose active TB in TB/HIV co-infected patients, especially in 
patients with CD4 T cell counts less than 200 cells/mm3. In Study II, we demonstrated 
that BCG-specific IgG titers were significantly higher in TB/HIV co-infected patients 
compared to latent TB (Figure 11) and non-TB controls, but also higher compared to 
HIV-negative patients with active TB (Study II).  
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Figure 11. Mtb-specific IFN-γ production (QFTG) and BCG-specific plasmablasts (ALS) in 
HIV-negative and HIV-positive individuals with active TB (circles) or latent TB (squares). Red 
symbols represent patients with a CD4 T cell count < 200 cells/ml. The solid bars indicate the 
median values for each group while the dashed line indicates the cutoff. 
 
Accordingly, the sensitivity of the ALS assay was slightly higher in TB/HIV co-
infected (91%) compared to HIV-negative patients with active TB (86%) (Table 2). 
These results are very promising and suggest that the ALS could be used for effective 
diagnosis of active TB also among HIV-infected patients with low CD4 T cells counts.  
 
 
 
 
 
 
 
HIV infection could give rise to different types of B cell abnormalities; including 
selective loss of antigen-specific memory B cells [450] but also 
hypergammaglobulinemia and the production of polyclonal antibodies by activated 
naive B cells [451, 452]. Hypergammaglobulinemia has also been observed in TB and 
leprosy infections both in the presence and absence of HIV infection [453]. 
Hypergammaglobulinemia in HIV has been suggested to involve T follicular helper 
cells producing the B cell stimulatory cytokine IL-21 as well as IL-10 that may promote 
the differentiation of IgG-secreting plasma cells [454]. Interestingly, we have found up-
regulated mRNA levels of total IgG as well as IL-21, particularly in PBMC samples 
obtained from the TB/HIV co-infected patients included in Study II (unpublished 
observations). Moreover, significantly higher serum levels of total IgG have been found 
in patients with chronic HIV-1 infection compared to healthy controls and raised IgG 
levels were also found in HAART-naïve compared to HAART-treated HIV patients 
[455]. This increase in serum IgG correlated with high serum levels of the immune 
activation marker, soluble CD27, which could promote IgG-secretion by recently 
antigen-experienced B cells in vitro [455]. Thus, the continued exposure to microbial 
antigens during chronic infection with TB and/or HIV may enhance B cell activation 
and antibody-mediated immunity, especially in patients with impaired T cell responses. 
It will be important to continue and study the mechanisms behind the increased level of 
BCG-specific plasamblast responses in TB-infected as well as TB/HIV co-infected 
patients. Here, it would also be interesting to study the presence of different 
immunoglobulin isotypes (IgE, IgG1-4, IgM, IgA), the specificity of these antibodies 
and the cytokine profile in the ALS supernatants. 
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4.2.2.3 The basis of the ALS assay is different compared to conventional serology 
The theoretical basis for the ALS assay is that in a steady-state, migratory and IgG-
secreting plasmablasts among PBMCs are very low, but significantly elevated upon 
continuous antigen exposure ie. during active TB infection [433, 434]. HIV infection is 
also associated with an increased frequency of antibody-secreting short-lived 
plasmablasts [454]. Antibody-secreting cells leave the B cell follicles of the secondary 
lymphoid tissues as plasmablasts [433] and are later found in the bone marrow with the 
phenotype of mature plasma cells [456, 457]. Accordingly, antibody-secreting cells are 
temporarily present in the peripheral circulation of patients with inflammatory diseases 
[458]. Consistent with the findings of increased BCG-specific IgG titers detected in the 
ALS supernatants, we found significantly elevated levels of circulating CD3-
CD19+CD20-CD27highCD38high plasmablasts expressing membrane-bound IgG in 
PBMC samples from patients with active TB disease (Study II). It has been shown that 
plasmablasts migrate toward CXCL9, CXCL12 [433], CXCL10, and CXCL11 into the 
bone marrow and/or inflamed tissues [459], which is interesting as we found 
significantly elevated levels of CXCL9 and CXCL10 both in the lung and in the 
peripheral blood of patients with PTB (Study III).  
There are considerable differences between the ALS assay and conventional serology 
(Table 3). In contrast to the ALS assay, stable antibodies in serum are continuously 
present in the circulation because these are primarily produced by non-migratory 
plasma cells residing in bone marrow [460]. High levels of serum antibodies were 
previously shown in TB patients with severe disease [453, 461]. However, serology-
based studies generally show highly variable results including suboptimal sensitivity 
and specificity to detect active TB [462-465].  
In Study III, we used conventional serology to study the induction of mycobacteria-
specific IgG responses in patients with PTB and pleural TB. BCG-specific IgG titers in 
plasma as well as BAL fluid was significantly higher in active TB patients, particularly 
in TB/HIV co-infected patients, compared to healthy controls (Study III). Enhanced 
IgG titers were associated to increase IL-4 levels in HIV-negative patients, but not in 
HIV-positive patients, which may suggest that humoral immunity are differentially 
regulated in TB-infected and TB/HIV co-infected patients. 
 
4.2.3 T cell-based immunodiagnosis 
4.2.3.1 TST and QFTG are dependent on cellular immunity 
As described above, mycobacteria-specific plasmablasts should only be present in the 
circulation during active TB infection and not during latent TB infection or in healthy 
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individuals. In contrast, peripheral Mtb-specific effector memory T cells will persist 
[466] in patients with active TB and also in individuals with latent TB and therefore 
neither QFTG nor TST can discriminate active TB from latent TB [12]. Thus, the 
relevance of these tests become small in high-endemic countries, whereas the TST and 
QFTG assays can be successfully used to screen TB-exposed contacts in low-endemic 
countries where latent TB is rare [435]. It has also been shown that a combined use of 
TST and QFTG may increase the sensitivity of these assays to detect active TB [467]. 
Compared to TST, QFTG has increased specificity to detect TB in BCG-vaccinated 
individuals and in patients with exposure to or infection with non-tuberculous 
mycobacteria [468, 469]. However, the diagnostic performance of both TST and QFTG 
is dependent on the number of peripheral CD4 T cells [437]. We observed significantly 
reduced levels of CD3+ and CD4+ T cell numbers in blood from active TB patients 
compared to both latent TB cases and non-TB controls (Study II). Accordingly, IFN-γ 
production was significantly higher in HIV-negative individuals with latent TB and we 
found a positive correlation between IFN-γ and CD4 T cell counts in latent TB cases 
and also in patients with a local lymph node TB (Study II). In contrast to QFTG, active 
TB patients with low CD4 T cell counts had higher ALS responses and demonstrated 
an inverse correlation between BCG-specific IgG titers and blood CD4 T cell counts 
(Study II). A schematic outline of the differences between the ALS, QFTG and TST 
assays are shown in Table 4. 
In our Ethiopian study cohort, 21% QFTG-negative (15% false negative and 6% 
indeterminate) results were found among patients with active TB (Study II), which is 
in agreement with a meta-analysis performed in 2011 [470, 471]. As expected TB/HIV 
co-infected patients have a lower sensitivity of the QFTG [472] and consequently all 
our indeterminant QFTG-results were from TB/HIV co-infected patients. Interestingly, 
the performance of the QFTG as well as the T-SPOT.TB assays could be improved by 
using cells from the site of Mtb infection including BAL [473] and pleural [474] fluid 
samples instead of whole blood, since effector T cells are accumulated at the disease 
sites [473] . 
 
4.2.3.2 IP-10 is a promising biomarker that could improve diagnosis of TB 
Another immunodiagnostic biomarker of TB that has been suggested to be superior of 
IFN-γ, is detection of IFN-γ inducible protein10, IP-10 or CXCL10, which has been 
shown to be particularly more robust to detect active or latent TB in adults [475], 
young children [476] and in HIV-infected individuals with low CD4 cell counts  
[477-480]. Here, IP-10 may be a better biomarker of active TB disease compared to 
IFN-γ, since IP-10 is mostly produced by monocytes and macrophages rather than 
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CD4+ T cells. Importantly, even if IP-10 is an amplified signal of IFN-γ [481], a 
small number of IFN-γ-secreting cells is enough to induce large quantities of IP-10 
secretion. In line with this notion, we found significantly elevated levels of IP-10 in 
both BAL and plasma samples from patients with active PTB, even though the levels 
of IFN-γ were low in these patients (Study III). Here, we also found a strong 
negative correlation (r=-0.75; p<0.0001) between IP-10 and peripheral CD4 T cell 
counts and particularly high IP-10 levels in TB/HIV co-infected patients (Study III). 
Consistent with our results, IP-10 was shown to generate indeterminate results only 
with CD4 T cell counts < 50 cells/ml, whereas QFTG generated indeterminate results 
with CD4 T cell counts < 200 cells/ml [479]. Accordingly, the IP-10-based assay 
produced around 50% less indeterminate results when compared with QFTG [479]. 
IP-10 can be assessed in the same Mtb-stimulated and unstimulated plasma samples 
obtained using the QFTG kit, which provide the possibility to directly compare the 
diagnostic performance of IP-10 and IFN-γ in the patient cohorts [482]. Recently, it 
was reported that in vivo levels of IP-10 can also be measured in dried plasma spots 
placed on filter paper with a diagnostic accuracy comparable to the QFTG [483]. 
Such a simplified method is preferable to use in field studies and also provide the 
possibility to send samples via conventional mail over long distances for analysis 
without affecting the results. 
 
4.3 HOST IMMUNE RESPONSES IN MTB INFECTION 
Deregulated inflammation represents a central pathogenic feature of numerous 
microbial infections including TB [484]. To explore these immunopathogenic events in 
human TB, immune responses were studied at the local site of infection in Ethiopian 
children with lymph node TB (Study I) and also in adult Ethiopian patients with lymph 
node TB (ongoing Study IV) (Table 5), PTB or pleural TB (Study III). 
 
4.3.1 Altered tissue architecture and cellular composition in active TB 
In chronic infections such as TB, it is of significant relevance to study host-pathogen 
interactions in the infected tissue because effector T cells are recruited to and 
accumulate at the local site of bacterial replication [474, 485, 486]. Thus, our research 
group has developed a tissue-based technological platform to study expression and 
distribution of immune cells and effector molecules in Mtb-infected tissue biopsies 
(Study I and IV).  
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4.3.1.1 Granuloma formation and tissue remodeling is enhanced in lymph node TB 
Mtb induces formation of granulomas, collections of inflammatory myeloid cells and 
effector lymphocytes at the site of infection, which are important for the control of 
bacterial replication [86]. Therefore, it is important to study granulomatous 
inflammation in the physiological context of the Mtb-infected tissue. In Study I and 
IV, we had the opportunity to dissect local immune responses in Mtb-infected lymph 
nodes using microscopy and computerized image analysis. As expected, the lymphoid 
structure was replaced by confluent clusters of CD68+ macrophages surrounded mostly 
by CD3+ and CD4+ T cells forming granulomas of different sizes and shapes (Study I 
and IV). Accordingly, the cellularity of the Mtb-infected tissues was significantly 
lower compared to the reactive lymphadenitis controls (Study I and IV). Granuloma 
formation was typically accompanied with different types of tissue remodeling features 
such as necrosis, fibrosis and collagen deposition, ranging from solid to necrotic 
granulomas [43] (Study I and IV). In adult Mtb-infected lymph nodes, hematoxylin 
and eosin stained tissue sections were used to classify the TB granulomas into four 
stages (Table 6) depending on the morphological features of the granuloma (Study IV).  
 
 
 
 
 
 
 
 
Most of the granulomas in HIV-negative TB patients were non-necrotic (stage 1 and 2), 
whereas 66% of the granulomas in TB/HIV co-infected lymph nodes had extensive 
necrosis (stage 3 and 4) (Study IV) (Figure 12). This finding is in agreement with an 
IHC-based study performed with human lung tissue, which revealed extensive necrosis 
in TB/HIV co-infected patients [487]. Now, we plan to continue to dissect the local 
inflammatory responses in the tissue to determine which host factors could contribute 
to the fibrotic and necrotic process. 
 
 
 
 
 
 
 
Figure 12. Hematoxylin/eosin stain of paraffin-embedded lymph nodes showing the stages of 
granuloma formation in TB. The pie charts illustrate the relative granuloma staging in HIV-
negative TB patients compared to TB/HIV co-infected patients. gr=granuloma; ne=necrosis.  
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In contrast to lymph node TB in children, CD3+ T cells including CD4+ and CD8+ T 
cells were significantly reduced in lymph node tissue from both TB single-infected as 
well as TB/HIV co-infected patients (Study IV) (Figure 13). This may be because of 
more severe necrosis and fibrosis observed in adult compared to children´s lymph 
nodes (Study I and IV). CD68+ macrophage-rich granulomas contained an 
accumulation of Mtb-complex specific antigens including MPT64 (Study I) and M. 
bovis BCG (Study IV), which has previously been shown to be present in granulomas 
of both human lung [170] and lymph nodes [488]. Quantitative image analysis 
demonstrated significantly elevated levels of CD68+ macrophages and memory 
CD45RO+ T cells but decreased levels of CD20+ B cells in Mtb-infected lymph nodes 
from children (Study I). Similar to children, adult lymph nodes had reduced levels of 
CD20+ B cells but increased levels of CD68+ macrophages (Study IV) (Figure 12). 
Thus, B cell follicles were distorted in the Mtb-infected tissue and the normal lymphoid 
tissue was displaced by the granulomatous inflammation. Contrary, development of B 
cell containing secondary lymphoid structures have been described in close proximity 
to TB granulomas in the lung that may play a role in the control of local host-pathogen  
interactions [170]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. In situ image analysis of CD3, CD4, CD8, CD20 and CD68 protein expression (% 
positive area of total cell area) in lymph node tissue from adult TB patients. Representative IHC 
images are shown to the right. gr=granuloma; ne=necrosis; Bc foll=B cell follicle. 
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4.3.1.2 A shift towards a Th2 and/or Treg response is evident in lymph node TB 
Protective immunity in TB has been shown to be dependent on Th1 CD4+ T cells 
producing IFN-γ and TNF-α that support the differentiation of CTLs producing 
granule-associated cytolytic effector molecules [489]. mRNA analysis of cytokine 
profile, demonstrated a weak induction of Th1 cytokines in the Mtb-infected tissue 
including IFN-γ, TNF-α and IL-17 (Study I). Consequently, there was no up-
regulation of cytolytic and antimicrobial effector molecules, perforin and granulysin, in 
TB lymph nodes compared the control group, either at the mRNA or protein level 
(Study I). These results were consistent with our previous findings showing an 
impaired expression of perforin and granulysin in CD8+ T cells present in TB lung 
lesions of patients with chronic TB [490]. Instead, we found significantly elevated 
levels of IL-13 and TGF-β in TB compared to the controls (Study I and IV), which are 
known to support a shift towards a Th2 or Treg immune response. An anti-
inflammatory cytokine milieu may promote alternative macrophage activation and 
support the function of Treg cells [86]. Whereas IFN-γ promotes classical M1 
macrophage activation and a hostile milieu in the Mtb-infected tissue, Th2 cytokines 
such as IL-4 and IL-13 could promote activation of TGF-β-producing M2 
macrophages that contribute to collagen deposition in the inflamed tissue [96], which 
are typical traits of advanced TB disease. Here, TGF-β secretion by macrophages has 
been shown to be primarily associated with increased collagen synthesis by fibroblasts 
in chronic lung inflammation [491]. It has also been described that initial induction of 
iNOS expression in alveolar macrophages in the lung was followed by arginase 
expression, which would support a switch in macrophage polarization upon 
progression of TB disease [492]. 
mRNA of Mtb-infected lymph node tissue also demonstrated a significant increase in 
FoxP3 (Study I and IV) and IL-10 (Study IV) compared to the control groups. 
CD4+CD25+FoxP3+ Treg cells suppress Th1 cell responses in patients with TB [143], 
partly via the secretion of IL-10 and TGF-β [142]. Thus, the frequency of Treg cells in 
blood has been found to be higher in active TB patients compared to healthy controls 
and Tregs were also higher in sputum-positive compared to sputum-negative TB 
patients [493]. Successful anti-TB treatment reduced the peripheral Treg cell frequency 
to control levels in active TB patients [493].  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
4.3.2 Compartmentalization of immune responses in active TB 
Most studies on human TB involve cells from the peripheral blood, which may not 
provide a representative image of the specific immune responses present at the site of 
the infected organ or in the microenvironment of the granulomatous lesions [494]. 
Here, we were able to perform exclusive analysis of immune responses in lymph 
node granulomas (Study I and IV) and also in BAL and pleura from patients with 
active TB (Study III).  
 
4.3.2.1 Impaired CD8+ CTL responses are associated with elevated Treg cells in the 
TB granuloma 
The TB granuloma is a dynamic structure and the balance of local immune responses in 
the granuloma will dictate bacterial control and pathology. In Study I, we used our 
software programme (Leica Qwin) to specifically assess protein expression in the TB 
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granulomas compared to the total lymph node tissue obtained from children with a TB 
lymphadenitis (Figure 14). Microscopy and in situ image analysis demonstrated that 
CD8+ T cells expressing perforin and granulysin were scarce inside the granulomas, 
while granzyme A levels were expressed at similar levels inside and outside the 
granulomas (Study I). The importance of perforin and granulysin in killing intracellular 
Mtb has been previous been established [156]. Impaired CTL responses in the 
granulomas were associated to an increased proportion of both FoxP3+ Treg cells and 
TGF-β producing cells inside the granulomas (Study I). Here, TGF-β may be produced 
by Treg cells as well as Mtb-infected macrophages inside the granuloma. A higher 
abundance of activated CD8+ T cells around the granuloma may indicate defective 
trafficking of effector T cells into the lesions. Mtb-infected macrophages and CD4+ T 
cells may fail to provide proper chemokine responses to attract functional CTLs to the 
site of Mtb infection [495]. Interestingly, high local concentrations of iNOS were found 
inside the TB granuloma (Study I), which may contribute to bacterial control [496]. 
However, high levels of NO may also reduce IL-1-mediated inflammation indicating 
that NO has a dual role including antimicrobial activity and immunoregulatory 
functions in TB infection [497]. The relevance of NO in human TB remains to be fully 
elucidated. 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. In situ image analysis of protein expression inside lymph node granulomas 
compared to total lymph node tissue. Expression of CD68, iNOS, nitrotyrosine, M. bovis BCG 
as well as the Mtb-specific antigen MPT64 was significantly increased in the granuloma, which 
suggests that Mtb-infected macrophages expressing NO are accumulated inside the granuloma. 
Low expression of CD8+ CTLs and CD56+ NK cells as well as low perforin and granulysin 
inside the granuloma correlated with an enhanced expression of the Treg cell markers FoxP3, 
CTLA-4, GITR and TGF-β, suggesting active immunosuppression at the site of Mtb infection. 
 
While previous studies have shown that the granuloma is dominated by macrophages 
and CD4+ memory T cells, lower numbers of CD8+ T cells are mostly found in the 
peripheral rim surrounding the TB granuloma [85]. The functional importance of this 
lymphocyte arrangement is currently unclear. Elevated levels of FoxP3+ Treg cells have 
previously been observed inside granulomas in both murine and primate TB [139, 140].    
Hence, a substantial proportion of the CD4+ T cells may be Treg cells and not IFN-γ-
producing T effector cells. Migration of Treg cells but also Th2 cells to sites of 
bacterial replication could be important to control local inflammation, but may 
simultaneously inhibit essential Th1 responses. Such compartmentalization of local 
immune responses may result in impaired antimicrobial effector T cell responses and 
thus reduce contact-dependent killing of Mtb-infected cells inside the granuloma [498]. 
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4.3.2.2 Pro-inflammatory and Th2 responses are higher at the site of infection in the 
Mtb-infected lung compared to peripheral blood 
Previous studies on TB patients have demonstrated that similar T cell subsets are 
present in lung tissue and BAL fluid [499]. Multiplex protein analysis of BAL fluid 
samples (Figure 15) revealed that the pro-inflammatory cytokines IL-1β, IL-6 and 
TNF-α were significantly elevated in BAL fluid, while only IL-6 was up-regulated in 
blood from active PTB patients compared to uninfected controls (Study III). On the 
contrary, there was no induction of Th17 or Th1 effector cytokines, IFN-γ, IL-12 and 
IL-2, in the lung or peripheral circulation, while the Th2 cytokine IL-4 was 
significantly elevated at both these sites (Study III). Even though IFN-γ was only up-
regulated in plasma from TB/HIV co-infected patients, we could detect an elevated 
level of the IFNγ-inducible inflammatory chemokines, CXCL9 and CXCL10, both in 
lung and blood samples from patients with active TB (Study III). This may suggest the 
presence of an earlier peak of IFN-γ that had already declined, before proper immune 
control could be established. Interestingly, regulatory DCs selectively recruit Th1 cells 
via CXCL10 to inhibit Th1 proliferation [500]. Consistent with low levels of IFN-γ, we 
could not detect an increase in the T cell-chemoattractant CCL5 (Study III). IFN-γ 
may contribute to increased mRNA stability and expression of CCL5 [501, 502]. 
Instead, the only CC chemokine that was significantly up-regulated in BAL fluid from 
PTB patients was CCL4 (Study III). There is evidence that vaccination induces IL-17-
producing CD4+ T cells that populate the lung and, after Mtb challenge, trigger the 
production of chemokines that recruit IFN-γ-producing CD4+ T cells that contribute to 
control of bacterial growth [131]. IFN-γ promotes the development of a Th1 cell 
response [503] and synergizes with TNF-α to activate iNOS-production in 
macrophages. Moreover, IFN-γ-producing CD4+ T cells are required to induce robust 
CD8+ T cell responses [79]. Thus, a lack of IFN-γ may lead to a deficiency in both 
frequency and function of CD8+ CTL in TB. CCL5 is a key chemokine in the 
recruitment of CD4+ T cells and especially CD8+ T cells [504, 505] to the lung upon 
microbial infection and has been implicated in classical IFN-γ dominated Th1 
responses. IFN-γ cooperates with CCL5 to induce proliferation and activation of 
certain cytolytic lymphocyte subsets [506].  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Elevated levels of TNF-α and IL-4 together with CXCL10 and CCL4, while IFN-
γ and CCL5 remain low in BAL fluid from patients with pulmonary TB. The solid bar 
indicate the median for each group.  
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The above findings suggest an association between low IFN-γ at the site of infection 
(Study I and III) and impaired CD8 T+ cell responses (Study I). Instead, a strong up-
regulation of pro-inflammatory cytokines and chemokines in TB disease may promote 
severe inflammation in the lung (Study III). Up-regulation of TNF-α together with IL-
4 may lead to tissue destruction rather than immune control, since IL-4 has been 
reported to be involved in TNF-α-mediated toxicity and tissue fibrosis in patients with 
PTB [125]. In line with our results, TNF-α levels higher than 29 pg/ml and IL-4 levels 
higher than 13 pg/ml were considered to signal a high risk for TNF-α induced 
cytotoxicity and excess inflammation [507]. Interestingly, IL-1β has been shown to 
directly augment TNF-α signaling in macrophages through the up-regulation of TNF 
secretion and TNFR1 cell surface expression [508]. IL-1β and TNF-α can also induce 
the expression of MMP-1 in lung fibroblasts [212], which is the principal mediator of 
tissue destruction in the lung required to promote dissemination of disease [44]. 
Furthermore, it has been shown that the protective function of TNF-α can be inhibited 
by soluble TNFR that has been shown to be elevated in the lungs of BCG-infected mice 
[509].  
 
4.3.3 Polarization of immune responses in active TB 
Although a wide range of cytokines may contribute to the immunological balance in 
TB infection, a Th1 response dominated by TNF-α and IFN-γ are known as the 
principal mediators of protective immunity in TB [510], while IL-4 has the opposite 
effect. It has been shown that IL-4-producing T cells were increased in PBMCs of 
patients with untreated TB, which declined after two weeks of effective anti-TB 
treatment [511]. Thus, a delicate balance of Th1 and Th2 responses is of crucial 
importance to prevent the progression of TB disease [510] . 
 
4.3.3.1 Polarization of a Th2 cytokine response at the site of Mtb infection  
As described above, our findings demonstrated that neither Th1 (IFN-γ) or Th17 (IL-
17) cytokines were up-regulated in Mtb infected lymph nodes (Study I) nor in BAL 
fluid samples from patients with PTB (Study III). Moreover, Mtb-specific IFN-γ 
production was significantly decreased in blood from active TB patients as compared to 
individuals with latent TB (Study II). Instead, there was a significant up-regulation of 
IL-13 and TGF-β in tissue from lymph node TB (Study I and IV) while IL-4 was 
significantly up-regulated in BAL and blood from patients with lung TB (Study III). 
Elevated plasma levels of IL-4 and also IL-10 have been shown to coincide with 
increased levels of both TNF-α and IFN-γ in HIV-negative TB patients and also in 
TB/HIV co-infected patients as compared to healthy individuals [507]. This implies 
coexistence of elevated Th1 and Th2 responses in patients with TB. Decreased IFN-γ 
in active TB patients has also been associated to enhanced mRNA levels of FoxP3, 
TGF-β and IL-4 in blood cells [512]. We found a modest up-regulation of IFN-γ 
levels in blood of TB/HIV co-infected patients compared to the uninfected controls 
(Study III). TB/HIV patients may be able to maintain levels of IFN-γ, irrespective of 
their CD4 T cell counts or viral loads [507].  
Although a pathological role of a Th2 response dominated by IL-4 has been described 
in human TB [125], the properties of such a response has not been fully characterized. 
Apparently, it is difficult to distinguish IL-4 from IL-4delta2, a splice variant and 
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inhibitor of IL-4 [513]. mRNA analysis of blood and BAL cells obtained from TB 
patients showed that radiological findings correlated with a high IL-4/IFN-γ ratio [513]. 
After chemotherapy, IL-4 mRNA levels remained unchanged, whereas IL-4delta2 
increased in parallel with IFN-γ [513]. While HIV/TB co-infected patients showed 
increased levels of IL-4 and IFN-γ in both blood and BAL, an increase in IL-4delta2 
was only detected in BAL [514]. Moreover, healthy individuals with latent TB 
exhibited a selective increase of IL-4delta2, compared with both TB patients and non-
infected individuals [515]. Collectively, these data suggest that an increase in Th1 
responses has to be accompanied with an inhibition of Th2 responses in order to 
acquire long-term control of Mtb infection. 
It has been suggested that infection with helminth parasites could promote polarization 
of Th2 and Treg responses that could suppress imperative Th1 and Th17 responses 
upon concomitant infection with Mtb [516]. Parasitic gut infections are frequent in 
most regions where Mtb is endemic and a previous study from Ethiopia have shown 
that the TST result is affected by parasite infection [517]. However, deworming could 
improve the responsiveness to PPD [518]. In Africa, active TB has been shown to be 
associated with a low Th1 and a high Th2 response, whereas healthy exposed 
individuals have a high Th1/Th2 ratio [123]. In addition, TB patients with a favorable 
treatment outcome exhibit a higher Th1/Th2 ratio compared to patients with a poor 
clinical outcome [123]. The exact contribution of parasite-mediated Th2 polarization in 
human TB needs to further investigated. 
 
4.3.3.2 Th2 polarization may support the induction of CCL4 in active TB 
While we could not detect an up-regulation of CCL5 or the monocyte-chemoattractants 
CCL2 and CCL3, there was a significant up-regulation of CCL4 in BAL fluid from 
patients with active PTB (Study III). It is tempting to speculate that the lack of CCL5 
up-regulation (Study III) can partly explain low numbers of CD8+ T cells expressing  
perforin and granulysin in lymph node TB granulomas (Study I). It has been described 
that human T cells co-expressing CCL5 together with perforin and granulysin provide 
important protection in TB as these cells can kill Mtb-infected cells and also attract 
immune cells to the site of infection [519]. Instead, the CCL4 gene demonstrates 
significant association with increased susceptibility to TB [520] and accumulating data 
provide evidence of an immunoregulatory role of CCL4. Here, it was recently shown 
that BCG-activated CD8+CD39+ Treg cells expressed CCL4 and suppressed the 
proliferative response of antigen-specific CD4+ Th1 cells [521]. Such CCL4-producing 
CD8+ Tregs were found to be enriched in human lymph node granulomas [522]. 
Interestingly, IL-4 specifically elevates CCL4 expression and support polarization of 
regulatory Th2 cells in vivo that suppress Th1-mediated pathogenesis by decreasing the 
recruitment of activated CD8+ T cells into the pancreatic lesions of diabetic mice [523]. 
Our findings of elevated levels of CCL4 in the presence of a Th2 shift at the site of Mtb 
infection may suggest a synergistic interaction between CCL4 and IL-4 also in TB.  
 
4.3.3.3 Th2 polarization is associated to induction of humoral immunity in active TB 
Our findings suggest that loss of Th1-mediated cellular immune control is associated 
with enhanced activation of humoral immune responses in human TB. The shift 
towards a Th2 cytokine profile in patients with active TB, were found to correlate with 
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elevated antibody responses determined using the ALS assay (Study II) or 
conventional serology (Study III and IV) (Figure 16). These results are supported by 
previous studies showing that some pathogens elicit a mixture of protective, non-
protective and disease-enhancing antibodies [524]. Several studies suggest that B cells 
and antibodies are required to control mycobacterial infections [166, 525-528], while 
other studies fail to show any protective effects of antibodies [167]. Possibly, B cell 
responses may play a role in early protection and the induction of adaptive immunity in 
TB [529]; however, in the chronic phase of TB infection, enhanced antibody-responses 
may instead be a consequence of exacerbated TB disease. Humoral immunity is driven 
by soluble Mtb-antigens that are released and spread from destructive lesions present at 
the site of Mtb infection, especially in patients with extensive pulmonary TB including 
cavitary TB [530]. Accordingly, high levels of total and Mtb-specific serum antibodies 
have previously been shown in patients with advanced TB disease [453, 461].This is in 
agreement with the results from Study II, demonstrating that elevated levels of BCG-
specific IgG-secreting cells in the peripheral circulation of patients with active TB, 
were associated to reduced Mtb-specific IFN-γ production and more severe forms of 
TB disease. Similar to TB, Mycobacterium leprae-specific serum IgG1 antibodies in 
patients with leprosy show a direct correlation with bacterial load [531] Antibody 
responses and antibody-secreting CD138+ plasma B cells were also elevated at the site 
of M. leprae infection in skin lesions from patients with advanced disseminated forms 
of disease [532] which suggest that humoral immunity is not protective but rather 
associated to progression of mycobacterial disease.  
 
 
 
 
 
 
 
 
Figure 16. Mycobacteria-specific IgG titers were increased in the BAL fluid of patients with 
pulmonary TB. There was a positive correlation between IgG titers and protein levels of both 
IL-4 and CCL4 in the BAL fluid from HIV-negative PTB patients. The solid bars indicate the 
median for each group.  
 
4.3.3.4 SOCS3 may contribute to Th2 polarization in progressive TB disease 
To explore the mechanisms of cytokine polarization in human TB, we assessed 
mRNA expression of SOCS1 and SOCS3 proteins in BAL cells and PBMCs from 
patients with active TB (Study III). Similarly to IL-4 and CCL4, we found a local 
up-regulation of both SOCS 1 and SOCS 3 in in the lung of patients with PTB (Study 
III). Accordingly, in vitro Mtb infection of human primary macrophages induced a 
rapid and strong mRNA expression of both SOCS molecules (Study III). 
Interestingly, we found a positive correlation between both IL-4 and CCL4 with 
SOCS3 (Study III), but not with SOCS1, which may support a functional link 
between up-regulation of SOCS3 and Th2 cytokine polarization in patients with PTB. 
It has previously been determined that SOCS3 expression is significantly higher in 
Th2 than in Th1 cells [533]. Higher expression of SOCS3 have been detected in 
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whole blood from TB patients and patients with recurrent TB as compared to latent 
TB and this elevated SOCS3 expression was found to decrease simultaneously as 
IFN-γ increased after successful chemotherapy [534]. Moreover, SOCS3 
overexpression in mice promotes immune polarization of Th2 cells [314] and 
suppression of Th17 responses [316]. Likewise, T cells from patients with Th2-
mediated allergy have a high SOCS3 expression that correlates with disease 
pathology including the induction of antibody-mediated immunity [535]. Additional 
longitudinal studies may determine the usefulness of SOCS3 as a prognostic 
biomarker for the risk of TB in latent TB cases [536].  
 
4.3.3.5 Th2 polarization is enhanced in patients with severe forms of TB disease  
For patients most severely affected by TB, morbidity and mortality of the infection is 
partly the result of a pathological host immune response, which leads to tissue 
damage and loss of lung function [124, 537]. To investigate the role of a Th2 polarized 
immune response in severe forms of TB disease (Study III), an experienced radiologist 
graded disease severity in patients with PTB using chest X-ray findings into mild and 
moderate-to-severe TB disease according to the criteria described in Table 8. Thus, 
chest X-ray was used to grade disease severity in PTB but also to identify accumulation 
of fluid in the pleural space (Figure 17), which is consistent with extrapulmonary 
pleural TB. In the absence of pulmonary infiltrates or lesions, pleural TB is considered 
a milder form of TB disease [538]. 
 
 
Figure 17. Representative chest X-ray images from PTB patients showing mild and moderate-
to-severe TB disease. To the right, also chest X-ray image from a patient with pleural TB 
showing a collection of pleural fluid in the pleural cavity. The arrows indicate the 
lesion/infiltrate or pleural effusion. 
 
We found significantly elevated levels of IL-4, CCL4 and SOCS3 in HIV-negative 
patients with severe-to-moderate compared to mild TB disease (Study III) (Figure 18). 
This difference was not evident in TB/HIV co-infected patients. Atypical chest X-ray 
findings are common in TB/HIV co-infected patients and therefore radiological grading 
may become less powerful in this group of patients.  
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Figure 18. Increased expression of IL-4, CCL4 and SOCS3 in the BAL fluid of HIV-negative 
patients with moderate-to-severe PTB compared to patients with mild TB disease. The solid 
bars indicate the median for each group.  
  
Previously, IL-4 levels were shown to be relatively higher in patients with cavitary 
TB (moderate-to-advanced disease) [539]. In addition, patients with miliary TB 
(extensive TB disease), had significantly lower levels of IFN-γ but higher IL-4 levels 
in BAL fluid cells compared to peripheral blood [540]. These results suggest that 
there may be a skewing of the local cytokine profile toward a Th2 response, 
especially in patients with severe forms of TB disease [540]. This notion is supported 
by analysis of pleural fluid from patients with pleural TB, showing a significant up-
regulation of both IFN-γ and CCL5 in the absence of Th2 skewing including low levels 
of IL-4, CCL4 and SOCS3 (Study III). Accordingly, significantly higher IFN-γ levels 
have been shown in pleural fluid as compared to peripheral blood from patients with 
pleural TB, which confirm the presence of a predominant Th1 response in patients with 
a localized, less severe form of TB [540].  
A role of humoral immunity in severe forms of TB disease, is also supported by our 
findings of elevated BCG-specific plasmablasts responses (Study II) as well as higher 
plasma IgG titers (Study III) in TB/HIV co-infected patients with low CD4 T cell 
counts (< 200 cells/mm3). In addition, BCG-specific IgG titers in plasma were 
significantly higher in PTB patients (particularly in TB/HIV co-infected patients) 
compared to patients with extrapulmonary pleural TB (Study III) or lymph node TB 
(Study IV) (Figure 19). Collectively, these results suggest that we could use different 
forms of clinical TB as important tools or model systems to study immune polarization 
in human TB. 
 
 
Figure 19. Mycobacteria-specific IgG titers were increased in 
plasma from patients with PTB (n=35) compared to patients 
with either pleural TB (n=23) or lymph node TB (n=18) as 
well as uninfected controls (n=10). Results are presented as 
median +/- interquartile range.  
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5 CONCLUDING REMARKS 
This thesis provides novel insight into the immunopathogenic events that occur at the 
site of infection and in the peripheral circulation of patients with active TB. Based on 
studies of two clinical cohorts from Ethiopia, we were able to demonstrate that:  
1.) the novel ALS test can be used to detect active TB in both HIV-negative and HIV-
positive sputum-negative patients with PTB as well as EPTB. 
 Elevated BCG-specific IgG titers as well as IgG-expressing plasmablasts in 
samples from active TB patients compared to latent TB and non-TB controls. 
 Particularly high BCG-specific IgG titers in TB/HIV co-infected patients with 
low CD4 T cell counts and low Mtb-specific IFN-γ production. 
 Inverse correlation between BCG-specific IgG titers and peripheral T cell 
counts in patients with active TB.  
2.) progression of active TB is associated with polarization of immune responses from a 
Th1 towards a Th2 and/or immunoregulatory profile at the site of Mtb infection. 
 Low Th1/Th17 (IFN-γ, IL-17) responses and impaired perforin and granulysin 
expression in CD8+ CTLs.  
 Elevated Th2 (IL-4 or IL-13) responses as well as elevated IgG antibody 
responses and enhanced expression of CCL4 and SOCS-3. 
 Enhanced Treg cell (FoxP3, CTLA-4, GITR) responses and elevated levels of 
TGF-β and/or IL-10.  
The shift from a Th1 towards a Th2 cytokine/chemokine profile may explain the 
impaired CTL responses but enhanced antibody responses observed in patients with 
progression of clinical TB. Similarly, enhanced plasmablast responses detected with the 
ALS assay, were associated with lower IFN-γ responses and progression of TB, which 
suggest that the ALS assay represents an adverse immune response resulting from 
impaired cellular immunity in chronic TB. To improve clinical management of TB, we 
need new specific biomarkers ie. Mtb-specific plasmablasts, to facilitate an early and 
rapid diagnosis of active TB. Methods to follow disease prognosis in patients with 
active TB may also involve a combination of markers ie. IL-4/CCL4/SOCS3 used as 
novel immune response signatures to predict disease progression and outcome. 
In June 2009, our Study I was selected for press release by the American Journal of 
Pathology: “TB: hiding in plain sight”, that stress the importance to perform studies at 
the site of Mtb infection as we found a compartmentalization of immune responses in 
the granulomas. Likewise, it is an advantage to compare findings from peripheral blood 
to clinical samples obtained from the disease sites i.e. lung (BAL) or pleura. We aim to 
continue to explore the Th1/Th2 balance in the clinical material obtained from this 
thesis and to combine this work with functional experiments performed using in vitro 
model systems and virulent Mtb strains. In addition, the results from Study II were 
highlighted in the editorial of Thorax, 68(3):204-6, 2013: “TB immunodiagnosis: 
delving below the surface”. Now, we continue the important work with the ALS assay 
and currently test the diagnostic performance of the ALS among TB suspects recruited 
in a low-endemic setting in Sweden. In addition, the ALS assay is currently used to 
monitor treatment efficacy in a clinical trial in Ethiopia, where we test the antimicrobial 
effects of adjunctive immunotherapy with vitamin D and phenylbutyrate in HIV-
negative patients with PTB (ClinicalTrials.gov Identifier: NCT01698476). 
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